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Abstract 
Hydrogen deuterium exchange (HDX) coupled with mass spectrometry is widely used for 
probing protein structure and dynamics. Protein-ligand interactions usually induce a 
reduction in the measured HDX rates an effect that may be ascribed to stabilization of the 
protein structure.  This work aims to improve the general understanding of the changes in 
HDX patterns associated with ligand binding. 
We initially applied HDX for studying differences between oxy-hemoglobin (Oxy-
Hb) and aquomet-hemoglobin (Chapter 2). The results show that the α and β subunits 
respond differently to the oxy to aquomet transition with the heme binding pocket being 
destabilized in both cases. The results suggest that enhanced structural dynamics in the heme 
binding pocket may have adverse effects on heme-protein interactions.  
Chapter 3 focuses on the different scenarios that can be encountered in an HDX 
experiment upon ligand binding. Myoglobin and hemoglobin were used as model systems, 
focusing on the oxy and deoxy states of both proteins. Our results demonstrate that ligand 
binding can be stabilizing or destabilizing, leading to decreased or increased HDX rates 
respectively.  
In Chapters 4 HDX was used to probe the changes in structural dynamics of 
caseinolytic protease P (ClpP), an antibiotic drug target, after binding ADEP antibiotics. The 
mechanism of ADEP binding and the N-terminal structure of ClpP is not well understood 
with conflicting x-ray structures reported in literature. Our findings demonstrate that the N-
terminus of ClpP remains quite unstructured after ADEP binding, while belt region 
undergoes tightening.  
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Pin 1, a peptidyl prolyl isomerase, binding to a cyclic peptide inhibitor was studied in 
Chapter 5. Characterization of Pin1-CRYPEVEIC interactions by other techniques has been 
difficult. This study demonstrates that binding of the inhibitor triggers an overall stabilization 
of Pin 1. We identify a loop that interacts with basic sites of the ligand and that becomes 
destabilized upon ligand binding. This destabilization is ascribed to steric clashes between 
the peptide inhibitor and the protein 
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Chapter 1. Introduction 
1.1. Protein Structures  
Proteins play important roles in virtually all biological processes. While performing their 
functions many proteins undergo conformational changes which are essential for enzyme 
catalysis, transport, or energy conversion.1 Proteins adopt specific higher order structures via 
folding pathways that are still not fully understood.2  Misfolding can lead to diseases such as 
Alzheimer’s, Parkinson’s and other disorders.3 Even in the native state, proteins display 
considerable flexibility ranging from localized fluctuations to large conformational 
transitions. Ligand binding can trigger structural changes that lead to an increase or decrease 
in activity.4-5 Ligands that cause such conformational switching include inhibitors, metal ions 
and hormones.6  Deciphering protein conformational dynamics, folding pathways and ligand-
induced structural changes remain a fundamental research goal.  
 
 
1.2. Methods for Studying Protein Structure 
Numerous methods are available for the study of protein structures. These techniques are 
useful for both biochemical and clinical applications.  A brief discussion of the most 
common methods is given below. 
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1.3. "Traditional" Methods 
1.3.1.  X-ray crystallography 
X-ray crystallography remains the gold standard for solving the 3D conformation 
proteins with atomic resolution. This method is amenable to the study of protein 3D 
structures because X-ray wavelengths are comparable to the ~1Å range typically encountered 
for chemical bonds. A basic X-ray diffractometer includes a radiation source, and a detector 
(Figure 1-1). 
 
 
Figure 1-1: Schematic representation of an X-ray diffractometer 
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Protein X-ray crystallography was first implemented in the 1950s for solving the 
structure of hemoglobin and myoglobin.7 The atomic coordinates derived from X-ray 
crystallography are usually accompanied by displacement parameters also known as B-
factors. B-factor measures primarily the molecular disorder in the crystal and this is used as 
an indirect estimate of the dynamics of the protein. B-factor also measures other errors in 
addition to thermal motions in proteins crystal structures.
8
 It is widely recognized that 
proteins are not static structures and they constantly sample different conformational states in 
solution.9 The dynamic information on protein crystals are therefore limited because the 
proteins are modelled as single conformations.10-11 Although X-ray crystallography is widely 
used, crystal growth remains a challenge as not all proteins are amenable to crystallization. 
Also, X-ray data provide static pictures, thereby glossing over the intrinsic dynamics of 
proteins.  
 
1.3.2. Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectroscopy represents another tool for studying proteins. NMR is a 
phenomenon during which nuclei absorb particular radio frequencies in a strong external 
magnetic field. Depending on the type of interaction with the electromagnetic radiation 
insight can be gleaned into the nuclear identity and environment. For a nucleus to be NMR-
visible, it must have a non-zero spin.  Examples include 1H, 13C, 15N and 31P. The 
incorporation of deuterium into the protein backbone eliminates some NMR proton signals 
because 2H is not an NMR-active nucleus.12-13 NMR spectroscopy is a powerful technique for 
probing the structure and dynamics of biopolymers at the atomic level. NMR relaxation 
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measurements of 13C or 15N nuclei allow the study of molecular motions on the picosecond to 
microsecond time scales. Heteronuclear NMR can also be used to determine protein 
structures in solution.14 The technique, however, suffers size limitation problems.15 
 
1.3.3. Optical Methods 
Optical techniques are widely used for probing protein structural features. Examples 
include UV-Visible (UV-VIS) absorption spectroscopy, circular dichroism (CD) and 
fluorescence spectroscopy. These methods are quite popular because they are easy to use, 
sensitive, and proteins can be studied directly under physiological conditions with good 
sample recovery after analysis. They represent, however, low resolution tools.  
CD spectroscopy is an absorption-based method that measures the difference of left 
and right circularly polarized light. A CD spectrum is observable for chiral molecules. This 
technique is often used to evaluate secondary structural elements in proteins. Different 
structures generate characteristic CD signals. For example, proteins with a high α-helical 
content will give CD spectra with a minimum at 222 nm. β-sheet structures have a minimum 
around 215 nm, while for random coil structures the minimum appears at ~202 nm.16 Tertiary 
structure information can also be obtained when wavelengths between 250-350 nm are 
scanned.17 
UV-Vis spectroscopy works well when the protein contains a chromophore such as a 
conjugated π system. It is most useful for measuring protein concentrations. Also, small 
changes protein structure can be reflected in alterations of the absorption maxima. A good 
example is the conversion of oxyhemoglobin to deoxyhemoglobin. The change in the ligation 
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state of the heme chromophore is reflected by a shift in the absorption maxima from 415 nm 
to 430 nm.18  Absorbance (A) is defined as 
 
                                                                            log                                                      1.1               
 
where I0 is the initial light intensity and I is the transmitted intensity.19  The absorbance of a 
chromophore is related to its concentration according to Beer Lambert’s law. 
 
                                                                            ε C d                                                    1.2               
 
where d is the pathlength of the cuvette, C is concentration and ε is the molar absorption 
coefficient. 
Fluorescence spectroscopy is another optical technique that is routinely used for 
protein structural analyses. An electronically excited chromophore can relax to the ground 
state via photon emission to generate fluorescence. Tryptophan is the most commonly used 
intrinsic fluorophore.20 Fӧrster resonance energy transfer (FRET) is fluorescence technique 
that is particularly useful for probing molecular structure. In FRET, the energy transfer from 
an excited donor fluorophore to an acceptor depends on the distance between the two 
fluorophores. 21  FRET efficiency is defined as  
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Where R is the distance between donor and acceptor and Ro is the Fӧrster radius for E = 0.5. 
The sensitivity of FRET to distance has made it useful for probing distances within 3-
8 nm, for example in the context of protein folding.22-23 FRET can also lead to fluorescence 
quenching,  a phenomenon that has been applied to proteins containing heme, retinal or other 
non-fluorescent chromophores.24-27 
 
1.4. Mass Spectrometry  
Mass spectrometry (MS) has evolved as an indispensable tool in proteomics research. 
MS represents a weighing balance for ions in the gas phase. Two ionization techniques are 
used in proteomics research which allows the transfer of intact protein analytes into the gas 
phase under soft conditions. They are referred to as Matrix Assisted Laser 
Desorption/Ionization (MALDI-MS) and Electrospray Ionization (ESI).28 These ionization 
techniques allow the investigation of compounds with sizes ranging from a few Daltons (Da) 
to mega Daltons (MDa).29-30  MALDI was developed in 1985 by Karas and Hillenkamp.31 
For MALDI, the analytes are embedded in a solid matrix containing ultraviolet-absorbing 
molecules. With the help of a laser pulse, gaseous analyte ions are formed. 32-33  Because ESI 
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is exclusively used throughout this work, the ESI mechanism will be discussed in detail in 
the following section.  
 
1.4.1. The ESI Source 
ESI is a "soft" technique that is capable of transferring proteins and peptides from 
solution into the gas phase. ESI has several advantages over MALDI. ESI can be coupled to 
liquid chromatography (LC) which enables on-line separations. ESI generates multiply 
charged ions, as opposed to the singly charged ions produced by MALDI. This allows the 
detection of large analytes on mass spectrometers with limited m/z range.  
 
 
Figure 1-2: Schematic representation of an ESI source operated in positive mode 
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ESI occurs at atmospheric pressure. An analyte solution is infused into a metal 
capillary that is kept at a high voltage (~3kV in positive mode) relative to ground. This high 
voltage causes charge separation, where electrons are removed from solution (for example 
2H2O→ 4H+ + 4e- + O2). The solution at the tip of the capillary tip gets distorted into a 
Taylor cone which emits a mist of µm sized droplets (Figure 1-2).34 The initial droplets 
undergo rapid solvent evaporation. The charge density on the shrinking droplets continues to 
increase until surface tension equals Coulombic repulsion, also known as the Rayleigh limit. 
At this point, the number  of elementary charges e is: 35 
 
 
                                                                8                                                         1.4  
 
where R is the droplet radius,  is the vacuum permittivity, and  is the surface tension. 
Droplets close to  undergo jet fission. Several cycles of evaporation and jet fission 
ultimately produce gaseous analyte ions that can be detected by MS. 32-33, 36-37 To avoid the 
introduction of droplets and contaminants into the mass analyzer, a counter flow of gas is 
used for desolvation (usually N2).38  Nano-ESI is a variant of ESI that requires less sample 
volume than regular ESI. Nano-ESI droplets are believed to be at least 10 times smaller than 
those produced by regular ESI sources, leading to enhanced salt tolerance.39 This makes 
nano-ESI ideal for the study of large protein complexes in electrolyte-containing solutions.  
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The ESI mechanism is widely debated, three scenarios have been put forward to 
explain how charged droplets form analytes ions. These are referred to as the charge residue 
model (CRM), ion evaporation model (IEM), and chain ejection model (CEM) (Figure 1-3). 
37,40-41
 The CEM and CRM apply to proteins.  The CRM is thought to be operative for native 
(compact) proteins.41 The droplet undergoes several evaporation/fission cycles until all the 
solvent is removed, leaving a dried out protein ion. Unfolded proteins likely follow the CEM 
where the polymer chain exits the droplet with concomitant exchange of mobile charge 
carriers (protons).42 
 
 
 
Figure 1-3: Summary of protein ESI mechanism for (a) CRM for the transfer of globular 
proteins into the gas phase, and (b) CEM used for unfolded proteins. 
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1.4.2. Mass Analyzers 
The mass analyzer is used to separate charged analytes ions based on their m/z 
values. The charge state of a multiply protonated ion is given by 
 
                                                   " ⁄  $%  &'                                                       1.5 
 
Ion separation can be achieved by using electric and/or magnetic fields.43-44 Different mass 
analyzers, include quadrupoles, time of flight instruments, linear ion traps, 45 Orbitrap,46-48 
and Fourier transform ion cyclotron resonance devices.49 Some of these mass analyzers can 
be coupled together for tandem MS applications. Only the quadrupole and the time of flight 
operation will be discussed in the next section, because they are directly relevant to the 
experiments of this work. 
 
1.4.3. Quadrupole Mass Analyzer 
The quadrupole is by far the most common mass analyzer. It consists of two pairs of 
cylindrical rods with opposite charges (Figure 1-4). With a radio frequency (RF) voltage 
applied to the quadrupole, all ions generated in the source can be transmitted to the detector. 
In this "RF-only" mode, the quadrupole acts as an ion guide (Figure 1-4b). The quadrupole 
can also be used as a mass filter when choosing a combination of direct current (DC) and RF 
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voltages. In this "mass-resolving" mode, only ions with a certain m/z value can pass through 
the quadrupole while all other ions collide with the rods because their trajectories are 
unstable (Figure 1-4c). Single quadrupoles have been used in early mass spectrometers. In 
modern instruments it is more common to use them in conjugation with other analyzers. In 
particular Q-TOF instruments use quadrupole for precursor selection in tandem MS.50-54 
 
 
 
 
Figure 1-4: (a) Schematic representation of a quadrupole mass analyzer (b) RF only mode 
allows the passage of all analyte ions, and  (c) quadrupole in mass filter mode 
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1.4.4. Time of Flight (TOF) Mass Analyzer 
TOFs are able to separate ions of different m/z values without the need to scan across 
the mass range, a feature which is a huge advantage over quadrupole mass filters. In a TOF 
instrument, ions are accelerated into a flight tube by the application of a pusher pulse. Upon 
acceleration, the potential energy of the ion is converted into kinetic energy, and the time it 
takes for the ions to reach the detector can be calculated as follows 
 
                                                                     )*  +,-                                                                    1.6 
       
 
                                                                  /   12 "01                                                                   1.7 
 
From eq. 1.7, the time it takes to traverse the flight tube by an ion can be calculated as 
 
                                                                3  4 5" 12/                                                                   1.8 
 
where U, d, m, z and   represent the acceleration voltage, length of the flight tube, mass of 
the ion, charge state of the ion, and velocity of the ion, respectively. Equation 1.8 can be 
rewritten as: 
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Where   6    4 √2/:   is a parameter independent of the analyte 
With conventional TOF instruments, slight deviations in the velocities of ions are not 
corrected for, two ions of the same m/z value with slightly different velocities will arrive at 
the detector at different times, leading to low mass resolution. The introduction of reflectron 
compensates for these velocity differences. Most modern instruments use an orthogonal 
acceleration geometry (oa-TOF) where the pusher pulse is applied in a perpendicular 
direction towards the incoming ion beam. (Figure 1-5).  
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Figure 1-5: Schematic representation of an oaQ-TOF mass spectrometer equipped with a 
collision cell for collision-induced dissociation (CID). The red line indicates the ion 
trajectory. 
 
The ion travelling with a higher velocity penetrates the reflectron further than one with a 
lower velocity. This ensures that the two ions arrive at the detector at the same time leading 
to sharper peaks and better resolution.55  
 
1.5. Mass Spectrometry Based Methods for Characterizing Protein 
Structure and Dynamics. 
1.5.1. Covalent Labeling 
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Covalent labeling is a common approach for examining protein conformations. This 
method can probe the solvent accessibility of side chains. Exposed sites react with the 
covalent probe very quickly, while buried regions are protected (Figure 1-6).56  
 
 
 
 
Figure 1-6: Schematic representation of a covalent labelling experiment. Solvent accessible 
reactive residues become modified (in this case via oxidation) while protected residues 
remain unlabeled 
 
Hydroxyl radical (•OH) is a widely used covalent label because it is reactive and 
capable of labeling many types of residues. •OH  labeling occurs very rapidly with an 
estimated time scale of ~1 µs under properly optimized conditions which is useful for 
monitoring short lived folding intermediates.57 Quantitative analyses of oxidation patterns (or 
solvent accessibility) are usually conducted at the peptide level by subjecting the protein to 
enzymatic digestion prior to MS. Single residue resolution has also been reported using LC-
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MS/MS methods.58-60  Covalent labeling has been applied to the study of protein-protein 
interactions,61-62 protein-DNA complexes,63 integral membrane proteins binding studies64 and 
some in vivo experiments.65  
Although covalent labeling generates labels that are highly stable and relatively easy 
to detect, the analysis is complicated by the fact that differentially labeled peptides do not 
coelute during LC. Also, the introduction of covalent labels may alter the protein structure. 
This problem can be minimized by ensuring that the number of labels per protein is very 
low.66-67 
 
1.5.2. Covalent Cross Linking 
Covalent cross linking relies on the ability of two protein side chains, at an 
appropriate distance from each other, to undergo coupling upon exposure to a suitable cross-
linking agent (Figure 1-7). A variety of cross-linkers have been made, most of consist of two 
reactive sites (commonly alkyl chain). Lysines represent the most widely targeted type of 
cross-linking site. Cysteine and other residues can be used as well.68  The cross-linking agent 
can either be functionalized to probe Lys-Lys distances (homo-bifunctional linkers) or Lys-
Cys distances (hetero-bifunctional linkers). 
 17 
 
 
Figure 1-7: A schematic depiction of a crosslinking reaction, with Lysine residues shown in 
red. 
 
Cross-linking agents can also have variable spacer lengths.69 Similar to covalent 
labeling, an enzymatic cleavage step is almost always incorporated into the analysis. The 
analysis is complicated by the need to separate a small modified peptide fraction from a 
largely unmodified digest. This is even more challenging when protein interactions are being 
studied because the linker can react in a number of different ways.70 
 
1.5.3. Hydrogen Deuterium Exchange Mass Spectrometry 
Hydrogen deuterium exchange (HDX) is a powerful tool for probing the higher order 
structures and dynamics of protein.71 HDX coupled with ESI-MS has evolved as a useful 
technique for studying the conformation, dynamics and interactions of proteins in solution.72-
73
 HDX measurements can be used to locate binding sites, identify structural changes, and for 
distinguishing the populations of protein structures present during exchange.74-75 Different 
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studies have used HDX to examine protein-protein and protein-ligand interactions.76-80  HDX 
also allows the study of the conformation, dynamics and function of proteins larger than 40 
kDa. 81-83  
In HDX, protein is exposed to a solvent containing D2O or a fully deuterated protein 
is exposed to H2O. The former is known as exchange-in and the latter is referred to as 
exchange-out, with both experiments giving identical information. Regions of the protein that 
are not involved in hydrogen bonding exhibit a burst phase exchange kinetic, whereas 
regions that are in the interior of the protein or involved in hydrogen bonds, exchange at 
much slower rates.84 Depending on solvent accessibility and hydrogen bonding strength, 
different backbone amide (N-H) hydrogens undergo isotopic exchange at different rates.85 
Exchange can also occur at O-H, N-H and S-H sites on the side chains, but these deuteriums 
are lost during the LC step due to back-exchange. Thus, the side chains do not contribute to 
the measured mass shifts.86 The overall backbone HDX exchange mechanism for native 
proteins under continuous labelling conditions can be described as 
 
 
; < &=>?@A     ⇄          ; < &)@-@A     ⇄        ; < C)@-@A      ⇄     ; < C=>?@A        1.10 
          
 
where kop, kcl, and kch are the opening, closing and chemical exchange rates constants 
respectively.  Each amide hydrogens in a protein can exhibit a unique combination of kop, kcl 
and kch.  For exchange to occur in a protected region of the protein, the amide hydrogen of 
kch kop 
kcl 
kcl 
kop D2O 
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interest has to be solvent accessible which means the hydrogen bonds have to be transiently 
broken.87 
 
1.5.4.  EX1 and EX2 
Two limiting regimes are seen in HDX kinetics for a protein in the native state. They are  
EX1 and EX2: EX1 is not common at physiological pH.  In this scenario, the chemical 
exchange rate is faster than the closing rate (kch >> kcl) (Figure 1-8). The regime can be 
promoted in the presence of denaturants and high temperatures. The resulting exchange rate 
constant is simply  
                                                              6ex   6op                                                               1.11        
 
 
 
The EX1 regime is characterized by bimodal mass distribution (Figure 1-8) 
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Figure 1-8: Deuterium uptake in the EX1 regime 
 
The EX2 exchange regime is usually observed for native proteins at physiological pH where 
most labeling experiments take place with kcl>>kch. The exchange rate constant is given by  
 
                                                 6HDX   6op6cl 6ch  Eop6ch                                                       1.12          
 
where Kop is the equilibrium constant for the opening and closing events. This exchange 
regime is manifested via peak envelopes that shift to higher m/z values as the exposure time 
increases (Figure 1-9). 
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Figure 1-9: Deuterium uptake in the EX2 regime 
 
 
Finally, for an unfolded protein, the exchange kinetics is only dependent on the chemical 
exchange rate constant i.e.  
 
                                                      6HDX  6ch                                                                  1.13 
 
1.5.5. Effects of Temperature, pH and Composition on Exchange Rate 
The exchange rate of N-H hydrogens is dictated by the pH, temperature, solvent 
accessibility and hydrogen bonding. As noted, hydrogens in side chain as well as those in the 
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backbone can be exchanged with deuterium. Deuterium in the backbone is retained during 
HDX analysis, while side chains back to hydrogen during analysis.88 N-H groups are 
catalyzed by acid and base. The rate constant for chemical exchange can be expressed as: 
 
                                         6ch  6H $&+'  6OH $F&-'                                                   1.14 
 
where kH and kOH are rates of acid and base catalyzed exchange respectively. The exchange 
rate has a minimum at pH 2.5 - 3. The exchange kinetics are also dependent on temperature 
as dictated by the Arrhenius equation as shown below. 
 
                                                        GH 6=I  GH < a J:                                                 1.15       
 
 
 
1.5.6. General Workflow of HDX-MS Experiments 
The general procedure used in HDX-MS is illustrated in Figure 1-10. The experiment can be 
conducted at the intact protein level, or in a spatially-resolved manner with protease 
digestion. 
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Figure 1-10: General protocol for an exchange-in HDX-MS experiment 
 
Isotopic exchange is initiated with the folded protein incubated in D2O buffered to the 
desired pH. Aliquots are removed at selected labelling times ranging from a few seconds to 
several days. After the deuterium exchange-in step, HDX is quenched by decreasing the pH 
to 2.4 and the temperature to 0oC. The intact protein can then be analyzed for global 
exchange kinetics. The LCMS analysis is usually carried out within a short time to prevent 
back exchange.  
To obtain HDX kinetics information on small regions of the protein, the protein is 
subjected to proteolysis using an immobilized pepsin column or other acid-active protease 
under quench conditions. The use of high pressure during proteolysis can enhance digestion 
efficiency.89-90 The resulting peptides are retained on a trapping column before being 
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transferred to an analytical column for reverse phase LC to determine the level of deuterium 
incorporated in the different segments.88,91 A schematic representation of a state-of-the-art 
digestion/desalting and separation fluidic unit for HDX-MS is shown in Figure 1-11.  
To avoid carryover in the experiments, washing steps between injections are usually 
incorporated into the protocol.92-93 For peptide analysis, MS/MS experiments have to be 
carried out first to identify peptides before the actual deuteration experiments. This is 
because pepsin is a nonspecific protease which complicates the identification of peptides 
after deuteration.  The introduction of software packages have helped in minimizing the 
problem of peptide analysis in HDX workflows.94-99 Nepenthesin is another acidic protease 
that has been used in HDX protocols.100 
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Figure  1-2: Layout of a typical fluidics unit for “bottom-up” proteolytic digestion HDX/MS 
experiments. (A) Isocratic flow (red) delivered by an auxiliary solvent module (ASM) moves 
the protein from the sample loop to a pepsin column for digestion. The resulting peptides are 
retained on a short trapping column. (B) Switching of the six-port valve allows the 
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proteolysis products to be washed off the trapping column via flow from a binary solvent 
module (BSM) which delivers a water/acetonitrile gradient (blue). The peptides are separated 
on a reversed-phase analytical column that is coupled to the ESI source of a mass 
spectrometer (MS). Reprinted with permission from Konermann et. al (2014) ACS.97 
 
 
Back exchange still remains a major problem in HDX-MS experimental protocols. 
Back exchange washes out the deuterium pattern incorporated into the protein during the 
labelling process.101 This can be mitigated by conducting the digestion and LC workflow in a 
short period of time at 0oC. Recent studies have also shown that the use of freezing point 
depressants can significantly reduce the amount of back exchange.102,91 
 
1.6. Scope of Thesis  
Proteins are not static structures but dynamic systems that undergo fluctuations in 
which hydrogen bonds are constantly opened and reclosed. The degree of fluctuation can be 
modulated by external stimuli stabilize or destabilize the proteins. Protein-ligand interactions 
in HDX experiments usually induce a reduction in the measured HDX rates, and this is 
usually ascribed to stabilization of the protein structure.103-104,77  
The objective of this research is to improve the understanding of changes in HDX 
patterns that are associated with protein-ligand binding. Ultimately, these efforts should 
provide insights into protein conformational dynamics, structures, and ultimately function. 
Oxy-Hb and aquomet-Hb represent widely used MS test analytes and previous MS 
studies have paid little attention to the differences between them by assuming that they both 
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share the same solution phase properties.  In Chapter 2, the structural dynamics in oxy-Hb 
and aquomet-Hb were compared using HDX-MS. The results indicate a global stabilization 
in Oxy-Hb with some destabilization in the heme binding pocket which is a possible 
explanation for heme release in aquomet-hemoglobin. 
HDX experiments are usually carried out with the expectation that ligand binding will 
induce a reduction in the deuteration rates of the protein. In Chapter 3, the effect of ligands 
binding to hemoglobin and myoglobin was studied using HDX-MS. This chapter explores 
the different scenarios that can be encountered in an HDX experiment upon ligand binding. 
The experiments in this chapter suggest that proteins can be globally stabilized or 
destabilized after ligand binding. The results further show that it is possible to have both 
scenarios in a single protein after ligand binding while some regions of the protein 
experience  no appreciable change at all. 
ClpP is a protease complex responsible for the degradation of substrate proteins in 
bacteria. The mechanism of pore opening in ClpP has been a topic of debate in literature with 
different views. In Chapter 4, HDX-MS was used to study the interaction between 
Caseinolytic Protease (ClpP) an antibacterial drug target and its ligand ADEP. The findings 
from this chapter demonstrate that binding of a ligand can trigger conformational changes 
both at the binding site and at allosteric sites far from it with hydrophobic interactions 
playing a major role at the opening of the ClpP axial pore.  
Peptidyl-prolyl isomerases (PPIase) catalyze the cis-trans conversion of X-pro bonds. 
Pin 1 is a PPIase involved in cell cycle regulation making it a promising anticancer target. In 
Chapter 5, the binding of a cyclic peptide to Pin1 isomerase was monitored using HDX-MS. 
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The experiments in this chapter were able to identify a loop region of residues which may 
have been responsible for the inability of researchers to crystalize Pin 1 with its ligands. The 
results also indicate that protein ligand interactions can result in both stabilization and 
destabilization of the protein structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
 
1.7. References 
1. Marcsisin, S. R.; Engen, J. R., Hydrogen exchange mass spectrometry: what is it and 
what can it tell us? Anal. Bioanal. Chem. 2010, 397, 967-972. 
 
2. Dill, K. A.; Ozkan, S. B.; Shell, M. S.; Weikl, T. R., The Protein Folding Problem. 
Annu. Rev. Biophys. Biomol. Struct. 2008, 37, 289-316. 
 
3. Prusiner, S. B., A Unifying Role for Prions in Neurodegenerative Diseases. Science 
2012, 336, 1511-1513. 
 
4. Kiefhaber, T.; Bachmann, A.; Jensen, K. S., Dynamics and mechanisms of coupled 
protein folding and binding reactions. Curr. Op. Struct. Biol. 2012, 22, 21-29. 
 
5. Boehr, D. D.; Nussinov, R.; Wright, P. E., The role of dynamic conformational 
ensembles in biomolecular recognition. Nat. Chem. Biol. 2009, 5, 789-796. 
 
6. Robinson, C. V.; Sali, A.; Baumeister, W., The molecular sociology of the cell. 
Nature 2007, 450, 973-982. 
 
7. Kendrew, J. C.; Bodo, G.; Dintzis, H. M.; Parrish, R. G.; Wyckoff, H.; Phillips, D. C., 
A Three-Dimensional Model of the Myoglobin Molecule Obtained by X-Ray Analysis. 
Nature 1958, 181 (4610), 662-666. 
 
8. Frauenfelder, H.; Petsko, G. A.; Tsernoglou, D., Temperature-dependent X-ray 
diffraction as a probe of protein structural dynamics. Nature 1979, 280, 558-563. 
 
9. Frauenfelder, H.; Sligar, S. G.; Wolynes, P. G., The Energy Landscape and Motions 
of Proteins. Science 1991, 254, 1598-1603. 
 30 
 
10. Frauenfelder, H.; Chen, G.; Berendzen, J.; Fenimore, P. W.; Jansson, H.; McMahon, 
B. H.; Stroe, I. R.; Swenson, J.; Young, R. D., A unified model of protein dynamics. Proc. 
Natl. Acad. Sci. U.S.A. 2009, 106, 5129-5134. 
 
11. DePristo, M. A.; de Bakker, P. I.; Blundell, T. L., Heterogeneity and inaccuracy in 
protein structures solved by X-ray crystallography. Structure 2004, 12, 831-838. 
 
12. Woodward, C., Is the slow-exchange core the protein folding core? Trends Biochem. 
Sci. 1993, 18, 359-360. 
 
13. Li, R.; Woodward, C., The hydrogen exchange core and protein folding. Protein 
Science 1999, 8 (8), 1571-1590. 
 
14. Wuthrich, K., NMR Studies of Structure and Function of Biological Macromolecules 
(Nobel Lecture). Angew. Chem. Int. Ed. 2003, 42 3340 –3363. 
 
15. Wand, A. J., Dynamic activation of protein function: A view emerging from NMR 
spectroscopy. Nat. Struct. Biol. 2001, 8, 926-931. 
 
16. Brahms, S.; Brahms, J., Determination of Protein Secondary Structure in Solution by 
Vacuum Ultraviolet Circular Dichroism. J. Mol. Biol. 1980, 138, 149-178. 
 
17. Kelly, S. W.; Jess, T. J.; Price, N. C., How to Study Protein by Circular Dichroism. 
Biochim. Biophys. Acta 2005, 1751, 119-139. 
 
18. Antonini, E.; Brunori, M., Hemoglobin and Myoglobin in Their Reactions With 
Ligands. North-Holland Publishing Company: Amsterdam, London, 1971; Vol. 21. 
 
19. Skoog, D. A., Principles of Instrumental Analysis. Brooks/Cole Thomson Learning: 
Toronto, 1998. 
 31 
 
20. Pan, Y.; Brown, L.; Konermann, L., Mapping the Structure of an Integral Membrane 
Protein under Semi-Denaturing Conditions by Laser-Induced Oxidative Labeling and Mass 
Spectrometry. J. Mol. Biol. 2009, 394, 968-981. 
 
21. Förster, T., Ann. Phys. 1948, 2, 55-75. 
 
22. Munoz, V., Conformational Dynamics and Ensembles in Protein Folding. Annu. Rev. 
Biophys. Biomol. Struct. 2007, 36, 395-412. 
 
23. Schuler, B.; Lipman, E. A.; Eaton, W. A., Probing the free-energy surface for protein 
folding with single-molecule fluorescence spectroscopy. Nature 2002, 419, 743-747. 
 
24. Elöve, G. A.; Bhuyan, A. K.; Roder, H., Kinetic Mechanism of Cytochrome c 
Folding: Involvement of the Heme and Its Ligands. Biochemistry 1994, 33, 6925-6935. 
 
25. Lee, S. P.; Engman, K. C.; Tezcan, F. A.; Gray, H. B.; Winkler, J. R., Structural 
features of cytochrome c' folding intermediates revealed by fluorescence energy-transfer 
kinetics. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14778-14782. 
 
26. Kawamura-Konishi, Y.; Kihara, H.; Suzuki, H., Reconstitution of myoglobin from 
apoprotein and heme, monitored by stopped-flow absorption, fluorescence and circular 
dichroism. Eur. J. Biochem. 1988, 170, 589-595. 
 
27. Shen, L. L.; Hermans, J., Kinetics of Conformation Change of Sperm-Whale 
Myoglobin. I. Folding and Unfolding of Metmyoglobin following pH jump. Biochemistry 
1972, 11, 1836-1841. 
 
28. Kaltashov, I. A.; Eyles, S. J., Mass Spectrometry in Structural Biology and 
Biophysics: Architecture, Dynamics, and Interactions of Biomolecules. 2nd ed.; Wiley: 
Hoboken, NJ, 2012. 
 
 32 
 
29. Heck, A. J. R.; Van den Heuvel, R. H. H., Investigation of intact protein complexes 
by mass spectrometry. Mass Spectrom. Rev. 2004, 23, 368-389. 
 
30. Berkenkamp, S.; Kirpekar, F.; Hillenkamp, F., Infrared MALDI Mass Spectrometry 
of Large Nucleic Acids. Science 1998, 281, 260-262. 
 
31. Karas, M.; Bachmann, D.; Hillenkamp, F., Influence of the wavelength in high-
irradiance ultraviolet laser desorption mass spectrometry of organic molecules. Anal. Chem. 
1985, 57, 2935-2939. 
 
32. Fenn, J. B., Electrospray Wings for Molecular Elephants (Nobel Lecture). Angew. 
Chem. Int. Ed. 2003, 42, 3871-3894. 
 
33. Kebarle, P.; Verkerk, U. H., Electrospray: From Ions in Solutions to Ions in the Gas 
Phase, What We Know Now. Mass Spectrom. Rev. 2009, 28, 898-917. 
 
34. Wu, X.; Oleschuk, R. D.; Cann, N. M., Characterization of microstructured fibre 
emitters: in pursuit of improved nano electrospray ionization performance. Analyst 2012, 
137, 4150-4161. 
 
35. Rayleigh, L., On the Equilibrium of Liquid Conducting Masses charged with 
Electricity. Phil. Mag. 1882, 14, 184-186. 
 
36. Cech, N. B.; Enke, C. G., Practical Implication of Some Recent Studies in 
Electrospray Ionization Fundamentals. Mass Spectrom. Rev. 2001, 20, 362-387. 
 
37. Nguyen, S.; Fenn, J. B., Gas-phase ions of solute species from charged droplets of 
solutions. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 1111-1117. 
 
38. Covey, T. R.; Thomson, B. A.; Schneider, B. B., Atmospheric Pressure Ion Sources. 
Mass Spectrom. Rev. 2009, 28, 870-897. 
 33 
 
39. Juraschek, R.; Dulcks, T.; Karas, M., Nanoelectrospray - More than just a Minimized-
Flow Electrospray Ionization Source. J. Am. Soc. Mass Spectrom. 1999, 10, 300-308. 
 
40. Hogan, C. J.; Carroll, J. A.; Rohrs, H. W.; Biswas, P.; Gross, M. L., Combined 
Charged Residue-Field Emission Model of Macromolecular Electrospray Ionization. Anal. 
Chem. 2009, 81, 369-377. 
 
41. Konermann, L.; Ahadi, E.; Rodriguez, A. D.; Vahidi, S., Unraveling the Mechanism 
of Electrospray Ionization. Anal. Chem. 2013, 85, 2-9. 
 
42. Sciuto, S. V.; Liu, J.; Konermann, L., An Electrostatic Charge Partitioning Model for 
the Dissociation of Protein Complexes in the Gas Phase. J. Am. Soc. Mass Spectrom. 2011, 
22, 1679-1689. 
 
43. Watson, J. T., Introduction to Mass Spectrometry. third ed.; Lippincott - Raven: 
Philadelphia, New York, 1997. 
 
44. Roboz, J., Mass Spectrometry: Instrumentation and Techniques. Wiley: New York, 
1968. 
45. Douglas, D. J.; Frank, A. J.; Mao, D., Linear Ion Traps in Mass Spectrometry. Mass 
Spectrom. Rev. 2005, 24, 1-29. 
 
46. Makarov, A., Electrostatic Axially Harmonic Orbital Trapping: A High-Performance 
Technique of Mass Analysis. Anal. Chem. 2000, 72, 1156-1162. 
 
47. Scigelova, M.; Makarov, A., Orbitrap Mass Analyzer - Overview and Applications in 
Proteomics. Proteomics 2006, 6 Suppl. 2, 16-21. 
 
48. Zubarev, A. R.; Makarov, A., Orbitrap Mass Spectrometry. Anal. Chem. 2013, 85, 
5288-5296. 
 
 34 
 
49. Marshall, A. G.; Hendrickson, C. L.; Jackson, G. S., Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometry: A Primer. Mass Spectrom. Rev. 1998, 17, 1-35. 
 
50. Iribarne, J. V.; Dziedzic, P. J.; Thomson, B. A., Atmospheric pressure ion evaporation 
- mass spectrometry. Int. J. Mass. Spectrom. 1983, 50, 331-347. 
 
51. Yamashita, M.; Fenn, J. B., Electrospray Ion Source. Another variation on the Free-
Jet Theme. J. Phys. Chem. 1984, 88, 4451-4459. 
 
52. Fenn, J. B.; Mann, M.; Meng, C. K.; Wong, S. F.; Whitehouse, C. M., Electrospray 
ionization-principles and practice. Mass Spectrom Rev. 1990, 9, 37-70. 
 
53. Smith, R. D.; Loo, J. A.; Baringa, C. J.; Edmonds, C. G.; Udseth, H. R., Collisional 
Activation and Collision-Activated Dissociation of Large Multiply Charged Polypeptides and 
Proteins Produced by Electrospray Ionization. J. Am. Soc. Mass Spectrom. 1990, 1, 53-65. 
 
54. Mirza, U. A.; Cohen, S. L.; Chait, B. T., Heat-Induced Conformational Changes in 
Proteins Studied by Electrospray Ionisation Mass Spectrometry. Anal. Chem. 1993, 65, 1-6. 
 
55. Verentchikov, A. N.; Ens, W.; Standing, K. G., REFLECTING TIME-OF-FLIGHT 
MASS-SPECTROMETER WITH AN ELECTROSPRAY ION-SOURCE AND 
ORTHOGONAL EXTRACTION. Anal. Chem. 1994, 66 (1), 126-133. 
 
56. Mendoza, V. L.; Vachet, R. W., Probing Protein Structure by Amino Acid-specific 
Covalent Labeling and Mass Spectrometry. Mass Spectrom. Rev. 2009, 28, 785-815. 
 
57. Gau, B. C.; Sharp, J. S.; Rempel, D. L.; Gross, M. L., Fast Photochemical Oxidation 
of Protein Footprints Faster than Protein Unfolding. Anal. Chem. 2009, 81, 6563–6571. 
 
 35 
 
58. Gau, B. C.; Chen, J. W.; Gross, M. L., Fast photochemical oxidation of proteins for 
comparing solvent-accessibility accompanying protein folding: Data processing and 
application to barstar. BBA-Proteins Proteomics 2013, 1834 (6), 1230-1238. 
 
59. Li, X.; Li, Z.; Xie, B.; Sharp, J. S., Improved Identification and Relative 
Quantification of Sites of Peptide and Protein Oxidation for Hydroxyl Radical Footprinting. 
J. Am. Soc. Mass Spectrom. 2013, 24 (11), 1767-1776. 
 
60. Jumper, C. C.; Bomgarden, R.; Rogers, J.; Etienne, C.; Schriemer, D. C., High-
Resolution Mapping of Carbene-Based Protein Footprints. Anal. Chem. 2012, 84, 4411-4418. 
 
61. Zhang, H.; Gau, B. C.; Jones, L. M.; Vidavsky, I.; Gross, M. L., Fast Photochemical 
Oxidation of Proteins for Comparing Structures of Protein-Ligand Complexes: The 
Calmodulin-Peptide Model System. Anal. Chem. 2011, 83, 311-318. 
 
62. Jones, L. M.; Sperry, J. B.; Carroll, J. A.; Gross, M. L., Fast Photochemical Oxidation 
of Proteins for Epitope Mapping. Anal. Chem. 2011, 83, 7657-7661. 
 
63. Schorzman, A. N.; Perera, L.; Cutalo-Patterson, J. M.; Pedersen, L. C.; Pedersen, L. 
G.; Kunkel, T. A.; Tomer, K. B., Modeling of the DNA-binding site of yeast Pms1 by mass 
spectrometry. DNA Repair 2011, 10, 454-465. 
 
64. Orban, T.; Jastrzebska, B.; Gupta, S.; Wang, B.; Miyagi, M.; Chance, M. R.; 
Palczewski, K., Conformational dynamics of activation for the pentameric complex of 
dimeric g protein-coupled receptor and heterotrimeric G protein. Structure 2012, 20, 826-
840. 
 
65. Clatterbuck Soper, S. F.; Dator, R. P.; Limbach, P. A.; Woodson, S. A., In Vivo X-
Ray Footprinting of Pre-30S Ribosomes Reveals Chaperone-Dependent Remodeling of Late 
Assembly Intermediates. Mol. Cell 2013, 52, 506-516. 
 36 
 
66. Xu, Y.; Falk, I. N.; Hallen, M. A.; Fitzgerald, M. C., Mass Spectrometry- and Lysine 
Amidination-Based Protocol for Thermodynamic Analysis of Protein Folding and Ligand 
Binding Interactions. Anal. Chem. 2011, 83, 3555-3562. 
 
67. Zhou, Y. P.; Vachet, R. W., Covalent Labeling with Isotopically Encoded Reagents 
for Faster Structural Analysis of Proteins by Mass Spectrometry. Analytical Chemistry 2013, 
85 (20), 9664-9670. 
 
68. Klockenbusch, C.; O'Hara, J. E.; Kast, J., Advancing formaldehyde cross-linking 
towards quantitative proteomic applications. Anal. Bioanal. Chem. 2012, 404 (4), 1057-1067. 
 
69. Fischer, L.; Chen, Z. A.; Rappsilber, J., Quantitative cross-linking/mass spectrometry 
using isotope-labelled cross-linkers. J. Proteomics 2013, 88, 120-128. 
 
70. Leitner, A.; Walzthoeni, T.; Kahraman, A.; Herzog, F.; Rinner, O.; Beck, M.; 
Aebersold, R., Probing Native Protein Structures by Chemical Cross-linking, Mass 
Spectrometry, and Bioinformatics. Mol. Cell. Proteomics 2010, 9 (8), 1634-1649. 
 
71. Woodward, C.; Simon, I.; Tüchsen, E., Hydrogen exchange and the dynamic structure 
of proteins. Mol. Cell. Biochem. 1982, 48, 135-160. 
 
72. Chalmers, M. J.; Busby, S. A.; Pascal, B. D.; Southern, M. R.; Griffin, P. R., A Two-
Stage Differential Hydrogen Deuterium Exchange Method for the Rapid Characterization of 
Protein/Ligand Interactions. J. Biomol. Techniques 2007, 18, 194-204. 
 
73. Rand, K. D.; Adams, C. M.; Zubarev, R. A.; Jørgensen, T. J. D., Electron Capture 
Dissociation Proceeds with a Low Degree of Intramolecular Migration of Peptide Amide 
Hydrogens. J. Am. Chem. Soc. 2008, 130, 1341-1349. 
 
74. Miranker, A.; Robinson, C. V.; Radford, S. E.; Aplin, R.; Dobson, C. M., Detection 
of Transient Protein Folding Populations by Mass Spectrometry. Science 1993, 262, 896-900. 
 37 
 
75. Liu, Y.; Belcheva, A.; Konermann, L.; Golemi-Kotra, D., Phosphorylation-Induced 
Activation of the Response Regulator VraR from Staphylococcus aureus: Insights from 
Hydrogen Exchange Mass Spectrometry. J. Mol. Biol. 2009, 391, 149-163. 
 
76. Sperry, J. B.; Shi, X.; Rempel, D. L.; Nishimura, Y.; Akashi, S.; Gross, M. L., A 
Mass Spectrometric Approach to the Study of DNA-Binding Proteins: Interaction of Human 
TRF2 with Telomeric DNA. Biochemistry 2008, 47, 1797-1807. 
 
77. Zhu, M. M.; Rempel, D. L.; Du, Z. H.; Gross, M. L., Quantification of protein-ligand 
interactions by mass spectrometry, titration, and H/D exchange: PLIMSTEX. J. Am. Chem. 
Soc. 2003, 125 (18), 5252-5253. 
 
78. Hopper, E. D.; Pittman, A. M. C.; Tucker, C. L.; Campa, M. J.; Patz, E. F.; 
Fitzgerald, M. C., Hydrogen/Deuterium Exchange- and Protease Digestion-Based Screening 
Assay for Protein-Ligand Binding Detection. Anal. Chem. 2009, 81, 6860-6867. 
 
79. Hopper, E. D.; Roulhac, P. L.; Campa, M. J.; Patz, E. F.; Fitzgerald, M. C., 
Throughput and Efficiency of a Mass Spectrometry-Based Screening Assay for Protein–
Ligand Binding Detection. J. Am. Soc. Mass Spectrom. 2008, 19, 1303-1311. 
 
80. Rodriguez, A. D.; Dunn, S. D.; Konermann, L., ATP-Induced Dimerization of the 
FOF1 Epsilon Subunit from Bacillus PS3: A Hydrogen Exchange/Mass Spectrometry Study. 
Biochemistry 2014, 53, 4072-4080. 
 
81. Uzawa, T.; Nishimura, C.; Akiyama, S.; Ishimori, K.; Takahashi, S.; Dyson, H. J.; 
Wright, P. E., Hierarchical folding mechanism of apomyoglobin revealed by ultra-fast H/D 
exchange coupled with 2D NMR. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13859-13864. 
 
82. Krishna, M. M. G.; Lin, Y.; Englander, S. W., Protein Misfolding: Optional Barriers, 
Misfolded Intermediates, and Pathway Heterogeneity. J. Mol. Biol. 2004, 343, 1095-1109. 
 38 
 
83. Hughson, F. M.; Wright, P. E.; Baldwin, R. L., Structural Characterisation of a Partly 
Folded Apomyoglobin Intermediate. Science 1990, 249, 1544-1548. 
 
84. Woodward, C., Advances in Protein Hydrogen Exchange by Mass Spectrometry. J. 
Am. Soc. Mass Spectrom. 1999, 10, 672-674. 
 
85. Mitra, G.; Muralidharan, M.; Pinto, J.; Srinivasan, K.; Mandal, A. K., Structural 
Perturbation of Human Hemoglobin on Glutathionylation Probed by Hydrogen-Deuterium 
Exchange and MALDI Mass Spectrometry. Bioconjugate Chem. 2011, 22, 785-793. 
 
86. Rand, K. D.; Lund, F. W.; Amon, S.; Jorgensen, T. J. D., Investigation of amide 
hydrogen back-exchange in Asp and His repeats measured by hydrogen (1H/2H) exchange 
mass spectrometry. Int. J. Mass Spectrom. 2011, 302, 110-115. 
 
87. Skinner, J. J.; Lim, W. K.; Bédard, S.; Black, B. E.; Englander, S. W., Protein 
dynamics viewed by hydrogen exchange. Protein Sci. 2012, 21, 996-1005. 
 
88. Englander, J. J.; Rogero, J. R.; Englander, S. W., Protein Hydrogen Exchange Studied 
by the Fragment Separation Method. Anal. Biochem. 1985, 147, 234-244. 
 
89. Ahn, J.; Jung, M. C.; Wyndham, K.; Yu, Y. Q.; Engen, J. R., Pepsin Immobilized on 
High-Strength Hybrid Particles for Continuous Flow Online Digestion at 10 000 psi. Anal. 
Chem. 2012, 84 (16), 7256-7262. 
 
90. Jones, L. M.; Zhang, H.; Vidavsky, I.; Gross, M. L., Online, High-Pressure Digestion 
System for Protein Characterization by Hydrogen/Deuterium Exchange and Mass 
Spectrometry. Anal. Chem. 2010, 82, 1171-1174. 
 
91. Venable, J. D.; Scuba, W.; Brock, A., Feature Based Retention Time Alignment for 
Improved HDX MS Analysis. J. Am. Soc. Mass Spectrom. 2013, 24, 642-645. 
 39 
 
92. Majumdar, R.; Manikwar, P.; Hickey, J. M.; Arora, J.; Middaugh, C. R.; Volkin, D. 
B.; Weis, D. D., Minimizing Carry-Over in an Online Pepsin Digestion System used for the 
H/D Exchange Mass Spectrometric Analysis of an IgG1 Monoclonal Antibody. J. Am. Soc. 
Mass Spectrom. 2012, 23, 2140-2148. 
 
93. Fang, J.; Rand, K. D.; Beuning, P. J.; Engen, J. R., False EX1 signatures caused by 
sample carryover during HX MS analyses. Int. J. Mass Spectrom. 2011, 302, 19-25. 
 
94. Iacob, R. E.; Engen, J. R., Hydrogen Exchange Mass Spectrometry: Are We Out of 
the Quicksand? J. Am. Soc. Mass Spectrom. 2012, 23, 1003-1010. 
 
95. Fajer, P. G.; Bou-Assaf, G. M.; Marshall, A. G., Improved Sequence Resolution by 
Global Analysis of Overlapped Peptides in Hydrogen/Deuterium Exchange Mass 
Spectrometry. J. Am. Soc. Mass Spectrom. 2012, 23, 1202-1208. 
 
96. Kreshuk, A.; Stankiewicz, M.; Lou, X.; Kirchner, M.; Hamprecht, F. A.; Mayer, M. 
P., Automated detection and analysis of bimodal isotope peak distributions in H/D exchange 
mass spectrometry using HeXicon. Int. J. Mass Spectrom. 2011, 302, 125-131. 
 
97. Kan, Z.-Y.; Mayne, L.; Chetty, P. S.; Englander, S. W., ExMS: Data Analysis for 
HX-MS Experiments. J. Am. Soc. Mass Spectrom. 2011, 22, 1906-1915. 
 
98. Zhang, Z. Q.; Zhang, A.; Xiao, G., Improved Protein Hydrogen/Deuterium Exchange 
Mass Spectrometry Platform with Fully Automated Data Processing. Anal. Chem. 2012, 84 
(11), 4942-4949. 
 
99. Guttman, M.; Weis, D. D.; Engen, J. R.; Lee, K. K., Analysis of Overlapped and 
Noisy Hydrogen/Deuterium Exchange Mass Spectra. J. Am. Soc. Mass Spectrom. 2013, 24, 
1906-1912. 
 
 40 
 
100. Rey, M.; Yang, M. L.; Burns, K. M.; Yu, Y. P.; Lees-Miller, S. P.; Schriemer, D. C., 
Nepenthesin from Monkey Cups for Hydrogen/Deuterium Exchange Mass Spectrometry. 
Mol. Cell. Proteomics 2013, 12 (2), 464-472. 
 
101. Sheff, J. G.; Rey, M.; Schriemer, D. C., Peptide-Column Interactions and Their 
Influence on Back Exchange Rates in Hydrogen/Deuterium Exchange-MS. J. Am. Soc. Mass 
Spectrom. 2013, 24 (7), 1006-15. 
 
102. Amon, S.; Trelle, M. B.; Jensen, O. N.; Jorgensen, T. J. D., Spatially Resolved 
Protein Hydrogen Exchange Measured by Subzero-Cooled Chip-Based Nanoelectrospray 
Ionization Tandem Mass Spectrometry. Anal. Chem. 2012, 84, 4467-4473. 
 
103. Konermann, L.; Pan, J.; Liu, Y., Hydrogen Exchange Mass Spectrometry for 
Studying Protein Structure and Dynamics. Chem. Soc. Rev. 2011, 40, 1224-1234. 
 
104. Powell, K. D.; Ghaemmaghami, S.; Wang, M. Z.; Ma, L.; Oas, T. G.; Fitzgerald, M. 
C., A General Mass Spectrometry-Based Assay for the Quantitation of Protein-Ligand 
Binding Interactions in Solution. J. Am. Chem. Soc. 2002, 124, 10256-10257. 
 
 41 
 
Chapter 2. Comparative Analysis of Oxy-Hemoglobin and 
Aquomet-Hemoglobin by Hydrogen/Deuterium Exchange 
Mass Spectrometry 
2.1. Introduction 
Hemoglobin A (Hb), the oxygen carrier in red blood cells, is among the most thoroughly 
studied proteins.1-4 Hereditary Hb defects are associated with anemia and other pathological 
symptoms.5 Efforts are currently underway to design chemically modified Hbs for blood 
transfusions.6 
Hb has a (αβ)2 quaternary structure (Figure 2-1). Each α subunit is closely linked to 
one β subunit via a “packing” interface, resulting in two symmetrical heterodimers that are 
referred to as α1β1 and α2β2. In comparison, the contacts between α1 and β2 (as well as α2 
and β1) are weaker, forming the so-called “sliding” interface.5 O2 transport is mediated by 
allosteric switching between the oxy (R) and deoxy (T) states. In oxy-Hb the distal 
coordination sites of all four heme iron centers are occupied by O2, whereas in the deoxy 
state these sites are vacant. During the R-T transition α1β1 rotates by 15° relative to α2β2. 
Interactions across the sliding interface are less extensive in R, whereas T is stabilized by 
additional salt bridges.1-5 O2 binding is only possible if the heme iron is in the 2+ state. 
Autooxidation to Fe(3+) can take place under physiological stress, but also during protein 
isolation and storage. The aquomet-Hb generated in this way is dysfunctional and has the 
distal iron coordination sites occupied by water.7 Aquomet-Hb formation in vivo causes a 
weakening of the heme-protein interactions. This facilitates release of Fe(3+) heme from the 
 42 
 
protein and diffusion of the porphyrin into lipid membranes where it can trigger oxidative 
damage. Existing data provide little insights as to why heme dissociation from aquomet-Hb is 
more facile than from oxy-Hb.8 
 
 
Figure 2-1: X-ray structure of bovine Hb (carbon monoxide-bound Fe(2+) state, pdb file 
2qss 8). The subunit numbering follows the commonly used notation 1. Heme groups are 
shown in magenta. The sites of distal ligand binding to the heme iron (oxygen in oxy-Hb, and 
water in aquomet-Hb) are highlighted in red. 
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Although the properties of Hb have been explored in great detail, 1-5 there are still 
major gaps in the general understanding of this protein.4-9 New X-ray investigations revealed 
a host of conformations that differ from the canonical T and R states. The functional 
significance of these newly discovered conformers remains unclear.9-12 Wide-angle X-ray 
solution scattering13 and NMR spectroscopy14-15 point to marked differences between Hb in 
solution and in the crystallized state. As a result, many aspects related to Hb structure and 
function are more controversial today than they were 30 years ago.13 
In addition to its central biomedical role, Hb represents an important test system for 
the development of novel bioanalytical techniques. Mass spectrometry (MS), in particular, 
relies heavily on Hb as model protein.16-17 A key milestone was the development of “native” 
electrospray ionization (ESI)-MS for studies on intact Hb18-20 and other protein complexes.21-
23
 Those early successes18-20 paved the way for subsequent Hb dissociation experiments, ion 
mobility studies, and gas phase isotope exchange investigations.24-29 On-line ESI-MS has 
been used for probing Hb subunit interactions, highlighting the potential of this approach for 
monitoring self-assembly processes in solution.30-33 Desorption ESI (DESI)-MS34 and matrix-
assisted laser desorption/ionization (MALDI)-MS 35 investigations routinely use Hb for 
benchmarking purposes. The prevalence of Hb as a MS model system is due to the fact that 
the protein is readily available at low cost. Also, existing X-ray data 1-5,12 provide a 
comprehensive reference base for the development of MS-based structural biology tools. 
Backbone amide hydrogen/deuterium exchange (HDX) coupled with ESI-MS has 
become a widely used method for studying protein behavior in solution.36-38 Polypeptide 
regions that exhibit a high degree of conformational dynamics undergo rapid exchange, 
whereas HDX in rigid hydrogen-bonded segments is much slower. HDX/MS measurements 
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commence with protein exposure to a D2O-containing solvent. Aliquots taken at selected 
labeling times are quenched at acidic pH. Pepsin digestion and subsequent peptide analysis 
by liquid chromatography (LC)/ESI-MS are carried out at low temperature. Spatially-
resolved HDX kinetics can then be obtained by tracking the mass shifts of individual 
peptides. 
Of the three Hb forms mentioned above, only oxy-Hb and aquomet-Hb represent 
widely used MS test analytes.16-20,24-26,28-35 In contrast, MS investigations on deoxy-Hb are 
rare because they require an O2-free environment.39 Previous MS studies paid little attention 
to possible differences between oxy-Hb and aquomet-Hb, implicitly assuming that both share 
the same solution phase properties. This view is consistent with X-ray data, according to 
which oxy-Hb and aquomet-Hb crystallize in virtually identical conformations. Depending 
on the conditions, this common structure can be either the R state,5,40-41 or a conformation 
that is referred to as R2.42-43 Close examination of oxy and aquomet-Hb crystal structures 
reveals only small differences related to the iron positioning within the heme.5-44 
Nonetheless, it remains unclear in how far those X-ray data 5,40-44 provide solid evidence for 
the notion that oxy-Hb and aquomet-Hb exhibit the same structural and dynamic behavior in 
solution. It is also noted that there are no crystallographic investigations that employed dilute 
ammonium acetate which serves as de facto standard solvent for MS studies on Hb.18-19,24-
25,28-35
 
HDX/MS represents an obvious strategy for probing possible differences in the 
solution phase properties of the various Hb forms. Earlier HDX work examined the 
relationship between the oxy and deoxy states.39,45-46 The latter exhibits a higher degree of 
protection, consistent with the more rigid structure of the T conformation.1-4 Surprisingly, 
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there appear to be no prior HDX/MS-based comparative analyses of oxy-Hb and aquomet-
Hb. The goal of the current work is to close this gap. Despite the fact that oxy-Hb and 
aquomet-Hb adopt virtually the same crystal structures 5,40-44, our HDX/MS data reveal that 
their solution phase behavior exhibits significant differences. 
 
2.2. Experimental Procedures 
2.2.1. Materials 
Porcine pepsin and potassium ferricyanide were purchased from Sigma (St. Louis, MO, 
USA). Ammonium acetate was obtained from Fluka (St. Louis, MO, USA). D2O was from 
Cambridge Isotope Laboratories (Andover, MA). All chemicals were used as received. Oxy-
Hb was isolated from fresh bovine blood following established procedures,7-32 and stored at -
80 °C until further use. Protein concentrations are reported on a per-tetramer basis throughout 
this work. Hb solutions for all experiments contained 10 mM ammonium acetate. Aquomet-
Hb was produced by exposing oxy-Hb to excess potassium ferricyanide, followed by 
desalting on a size exclusion column.32 The level of covalent modifications due to side chain 
oxidation was found to be negligible for the protein samples used here, as reported 
previously32 (data not shown). The measured mass values of the two subunits were consistent 
with those calculated from the sequence of bovine Hb8, i.e., (15,053 ± 1) Da for α and 
(15,954 ± 1) Da for β. UV-Vis absorption spectra were recorded on a Cary 100 instrument 
(Varian, Mississauga, ON, Canada). pH values were measured using a Fisher (Waltham, 
MA) AB15 pH meter; these values are reported without isotope correction. 
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2.2.2. Hydrogen/Deuterium Exchange Mass Spectrometry  
150 µM Hb (in the oxy or aquomet states) in 10 mM ammonium acetate was mixed with 4 
volumes of D2O containing 10 mM ammonium acetate, resulting in a protein concentration 
of 30 µM with a measured pH of 7.2 at room temperature. 30 µL aliquots were removed at 
various time points ranging from 1 to 360 min after initiating labeling. The aliquots were 
quenched at pH 2.4 by addition of HCl on ice, followed by flash freezing in liquid nitrogen 
and storage at -80 oC. For digestion, the aliquots were rapidly thawed to ~0 oC and mixed 
with 5 µL pepsin stock solution (1 mM in aqueous acetic acid, pH 4.1) at pH 2.4 for 1 min on 
ice. The final Hb concentration was 20 µM. The resulting peptic fragments were desalted and 
separated within 15 min on an equilibrated reversed phase column (Jupiter 4 µ Proteo, C12, 
50 × 1 mm; Phenomenex, Torrance, CA) with an online prefilter (KrudKatcher; 
Phenomenex) coupled to a Waters UPLC pump at a flow rate of 100 µL min-1, using a 
water/acetonitrile gradient in the presence of 0.1% formic acid. The injection loop volume 
was 20 µL and the total amount of protein per injection was 400 pmol. The injection syringe, 
column, injector and solvent delivery lines were kept at ~0 °C. Mass analysis of peptides was 
performed on a Synapt HDMS instrument (Waters, Milford, MA) with source and 
desolvation temperatures of 80 and 300 °C respectively, a cone voltage of 30 V, and an ESI 
voltage of 3 kV. The identity of each peptide was confirmed by tandem MS based on the 
known sequence of bovine Hb (pdb code 2QSS 8). Zero time point controls (m0) for the 
correction of artifactual in-exchange were performed by exposing Hb to a mixture of D2O 
and quenching buffer, using the solutions described above. Controls for fully exchanged Hb 
(m100, for the correction of artifactual back exchange) were prepared by incubating 30 µM Hb 
in labeling solution at pH 2.4 for 9 h. Intact protein HDX measurements were performed 
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using a procedure similar to that described above, but by using a different column (Jupiter 5 
µm Proteo, C4, 50 mm × 1mm; Phenomenex) without pepsin digestion. Biolynx 4.1 
(Waters), HX-Express 47 and manual inspection were employed to analyze the centroid mass 
of all peptides as a function of labeling time. Deuteration levels were determined as  
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All HDX measurements were conducted in triplicate; error bars shown in the figures below 
correspond to standard deviations. 
 
2.3. Results and Discussion 
2.3.1. Optical Characterization of Hb Samples 
Prior to conducting MS experiments it is important to verify the properties of the protein 
samples. The UV-Vis absorption spectrum of Hb represents a sensitive probe of the heme 
oxidation and ligation state (Figure 2-2). After thawing, Hb samples obtained from fresh 
bovine blood exhibit an absorption spectrum with a dominant Soret signal at 415 nm, along 
with bands at 541 and 577 nm. The presence of these so-called γ, β, and α signals represents 
the hallmark of oxy-Hb.7  
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Figure 2-2: UV-Vis absorption spectra of oxy-Hb and aquomet-Hb in 10 mM ammonium 
acetate. The protein concentration was 3 µM for both samples. Differences in the intensity of 
the Soret peak are caused by the different molar absorption coefficients of the two forms 7. 
 
After ferricyanide treatment the bands at 541 and 577 nm disappear and the Soret maximum 
shifts to 405 nm, as expected for Fe(3+) with distal iron coordination by water.7,32 These 
spectral data confirm the authenticity of the oxy-Hb and aquomet-Hb samples used in this 
work. 
 
2.3.2. Global HDX Kinetics 
For comparing the solution phase behavior of oxy-Hb and aquomet-Hb, HDX/MS 
measurements were initially conducted on the intact subunits. Markedly different isotope 
exchange kinetics are observed for the oxy and aquomet forms (Figure 2-3). Throughout the 
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6 h experimental time window the deuteration levels of aquomet-Hb are higher (by up to 
10%) than those of oxy-Hb. These differences extend to both subunits. Clearly, the oxy  
aquomet transition induces a conformational destabilization, resulting in more pronounced 
conformational dynamics for aquomet-Hb than for oxy-Hb. This is despite the fact that both 
forms crystallize in virtually the same conformation. 5,40-43 
As noted in the Introduction, previous investigations demonstrated that deoxy-Hb 
exhibits lower HDX levels than oxy-Hb 39,45-46. That behavior is consistent with the presence 
of more extensive contacts across the sliding interface in deoxy-Hb relative to oxy-Hb.1-5 
Those different subunit interactions are reflected in the tetramer-dimer dissociation constant 
(Kd) which is 2 × 10-6 M for oxy-Hb, and <10-10 M for deoxy-Hb 8,48. It might be expected 
that the enhancement of conformational dynamics seen in Figure 2-3 upon oxy  aquomet 
conversion is also related to changes in interaction strength at the sliding interface. However, 
the dissociation constants of aquomet-Hb and oxy-Hb are indistinguishable.32 We therefore 
conclude that the enhanced dynamics seen for aquomet-Hb relative to oxy-Hb must be 
caused by an internal destabilization of the α1β1 and α2β2 units, rather than additional 
weakening of the sliding interface. 
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Figure 2-3: HDX kinetics of aquomet-Hb (open symbols) and oxy-Hb (filled symbols). The 
two panels show data for the intact α (top) and β subunits (bottom) of the tetramer. Lines 
represent biexponential fits according to eq. 2.2. 
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2.3.3. Spatially-Resolved HDX/MS Measurements 
A more detailed view of the protein dynamics in the oxy and aquomet states is obtained when 
analyzing the HDX kinetics at the peptide level. Peptic digestion of Hb yielded 30 fragments 
that had a sufficiently high signal-to-noise ratio for reliable deuteration measurements. The 
overall sequence coverage obtained in this way is 82% (Figure 2-4). Exchange occurs in the 
EX2 regime, evident from a lack of peak splitting in the isotope envelopes (data not shown). 
As expected from the intact protein data (Figure 2-3), most peptides exhibit higher HDX 
levels for aquomet-Hb than for oxy-Hb throughout the experimental time window (Figure 2-
5). However, there are several regions that display almost the same kinetics in both states 
(such as β7-13); a few peptides even show the opposite trend (α1-23, α67-80, α110-125, and α129-
136). This pattern reveals that the overall destabilization accompanying the oxy  aquomet 
transition does not affect all regions of the Hb tetramer to the same extent. 
 Many features of the measured HDX kinetics in Figure 2-5 are consistent with 
crystallographic data.8 Peptides that comprise helical regions generally show significant 
protection. For example, α99-106 and β102-109 exhibit the lowest deuteration levels, in line with 
their positioning in the central regions of helices αG and βG, respectively. By the same 
token, some of the most highly deuterated peptides such as α47-53 , α135-141, β1-8, and β41-47 
correspond to loops and termini that are expected to be relatively mobile. Interestingly, 
several other peptides show very limited protection, despite being located in regions that 
appear to be tightly folded in crystallized Hb.8 One of these is α119-125, suggesting that the 
αG-αH loop comprises more residues than seen in the X-ray structure.  
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Figure 2-4: Sequence of the Hb α and β subunits. Helices are denoted as rectangles. Peptic 
fragments are indicated below the sequence. Solid lines represent peptides used for data 
analysis, whereas dashed lines represent redundant fragments. Boxes above the sequence 
indicate helices. 
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Similarly, the high HDX levels of β7-13 indicate considerable fraying at the N-terminus of 
helix βA. Our data therefore support the view 13-15 that not all of the structural features seen 
in crystallized Hb adequately reflect the solution-phase behavior. 
To facilitate the discussion of the measured HDX data, deuteration percentages were 
mapped to the X-ray structure of the Hb subunits for t = 120 min (Figure 2-6a-d). 
Overlapping peptides can be used to approximate the HDX behavior of segments that do not 
directly correspond to proteolysis products.49 This case applies to peptides α107-125 and α119-125 
that exhibit 41% and 99% deuteration, respectively, in oxy-Hb.  
Thus, the average deuteration percentage of α107–118 can be estimated as [16×41% - 
5×99%] / 10 = 16%. This calculation takes into account the presence of prolines, as well as 
deuterium loss on the first two residues of each peptide.50 The adjacent peptide α99–106 shows 
an even lower deuteration level of 7%, thereby pinpointing helix αG as the most protected 
element in the α subunit (residues 99 – 118, blue in Figure 2-6a). Similarly, βG represents 
the most protected helix in the β subunit (green, Figure 2-6b). The four G helices retain high 
protection even after the oxy  aquomet transition (Figure 2-6c, d). The low deuteration 
levels are consistent with the role of αG and βG as deeply buried elements that 
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Figure 2-5: HDX kinetics of peptides covering the α and β subunits of aquomet-Hb (open 
symbols) and oxy-Hb (filled symbols). Residue numbers of the individual peptides are 
indicated in each panel. Lines are biexponential fits of the form 
)1()1(% 21 210 tktk eAeAAnDeuteratio −− −+−+=  where A0 is the fraction of amide backbone 
groups that undergoes burst phase labeling, and A1 and A2 are the fractions that undergo 
deuteration with apparent rate constants k1 and k2, respectively. 
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Figure 2-6: Mapping the HDX data of Figure 2-5 to the X-ray structure of bovine Hb 8 for t 
= 120 min. Using the orientation of Figure 2.1 as reference, the top row of panels in this 
Figure corresponds to α1, the bottom row represents β2. Colors in (a) - (d) represent 
deuteration percentages, as defined in the legend along the bottom. Gray elements in (a) - (d) 
were not covered by peptide mapping. Panels (e), (f): Deuteration differences, calculated as 
[aquomet - oxy] for t = 120 min. Colored regions correspond to |difference| > 5%. Segments 
that show elevated deuteration after oxy  aquomet conversion are depicted in red. 
Segments with reduced deuteration are shown in blue. In all six panels the ligand binding site 
on the heme is highlighted in cyan. 
 
 
form key anchoring points at the packing interface.8 Two other regions are quite 
highly protected in oxy-Hb, i.e., the central portions of αB and αH (green, Figure 2-6a).  
The last two panels of Figure 2-6 highlight the deuteration differences upon oxy  
aquomet conversion. Segments that show enhanced conformational dynamics are depicted in 
red, those that undergo rigidification are shown in blue. It is seen that changes in the β 
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subunit are not restricted to specific regions. Instead, the whole polypeptide chain 
experiences a global destabilization (Figure 2-6f). In contrast, α globin shows a more 
intricate behavior where enhancements in structural dynamics are largely confined to the 
vicinity of the heme (Figure 2-6e, red). The location of these red elements in Figure 2-6e is 
consistent with the expectation that the heme binding pocket should be the epicenter of any 
structural changes that accompany the transition from the Fe(2+)…O2 state to the 
Fe(3+)…H2O form. Interestingly, helix αA as well as a number of adjoining regions become 
stabilized after aquomet formation (Figure 2-6e, blue). These stabilized regions in the α 
subunit are more remote from the heme, and they are not heavily involved in inter-subunit 
contacts. Overall, Figures 2-6e and 2-6f reveal that α and β globin respond to the oxy  
aquomet conversion in a very different fashion. This behavior is surprising, when considering 
the very similar average conformations of α and β, their symmetrical positioning within the 
Hb tetramer, and their high sequence homology.8 
 
2.4. Conclusions 
To the best of our knowledge, this is the first HDX/MS investigation that compares the 
conformational dynamics of oxy-Hb and aquomet-Hb. The two forms adopt virtually the 
same crystal structures, yet they exhibit solution-phase dynamics that are clearly different. 
Our findings are consistent with earlier studies that noted limitations in the predictive power 
of crystallographic data for protein behavior in solution. 13-15,51 
Aquomet-Hb is known to show elevated rates of heme loss relative to oxy-Hb, 
although the reasons underlying this behavior remain incompletely understood. Heme loss is 
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of biomedical significance, because free Fe(3+) heme can incorporate into lipid membranes, 
thereby triggering oxidative damage.8 This process is of particular relevance after hemolysis, 
where oxy-Hb or deoxy-Hb are released from red blood cells. Binding to haptoglobin is a 
mechanism for sequestering free Hb in the blood plasma, thereby counteracting aquomet-Hb 
formation and heme release.52 Nonetheless, under some conditions there can still be free Hb 
molecules that undergo autooxidation to the Fe(3+) state.53 We propose that the enhanced 
structural dynamics observed here for aquomet-Hb are a key factor that facilitates Fe(3+) 
heme dissociation from the protein. It is likely that the enhanced structural dynamics in the 
heme binding pocket of α globin (red in Figure 2-6e) directly reflect the adverse effects of 
aquomet formation on the stability of the heme-protein interactions. 
 Finally, we note that one of the most intriguing questions in biological MS is to what 
extent supramolecular solution phase structures can be preserved upon transfer into the gas 
phase.54-57 Investigations targeting this issue typically rely on crystallographic data as 
surrogate for the actual solution phase structure of the system under investigation. As 
discussed above, this strategy is not always adequate.13-15,51 The special role of oxy-Hb and 
aquomet-Hb as widely used model analytes in MS 16-20,24-35 warrants a close examination of 
their solution phase properties. In contrast to information provided by static X-ray data,5,40-43 
our HDX/MS results demonstrate that the solution phase dynamics of the two forms exhibits 
marked differences. It is hoped that the observations of this work will benefit future 
investigations on the relationship between Hb behavior in solution and in the gas phase.  
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Chapter 3. Effects of Protein-Ligand Interactions on 
Hydrogen/Deuterium Exchange Kinetics: Canonical and Non-
Canonical Scenarios 
 
3.1.   Introduction 
Hydrogen/deuterium exchange (HDX) methods are widely used for monitoring protein-
ligand interactions. This approach relies on the fact that ligand binding can modulate the 
extent of protein structural fluctuations that transiently disrupt hydrogen bonds and expose 
backbone amides to the solvent. It is commonly observed that ligand binding causes a 
reduction of HDX rates. This reduction may be restricted to elements adjacent to the binding 
site, but other regions can be affected as well. Qualitatively, ligand-induced HDX protection 
can be rationalized on the basis of two-state models that equate structural dynamics with 
global unfolding/refolding. Unfortunately, such models tend to be unrealistic because the 
dynamics of native proteins are dominated by sub-global transitions and local fluctuations. 
Ligand binding lowers the ground state free energy. It is not obvious why this should 
necessarily be accompanied by a depletion of excited state occupancies, which would be 
required for a reduction of HDX rates. Here, we propose a framework which implies that 
ligand binding can either slow down or accelerate amide deuteration throughout the protein. 
These scenarios are referred to as “type 1” and “type 2”, respectively. Evidence for type 1 
binding is abundant in the literature, whereas the viability of type 2 interactions is less clear. 
Using HDX mass spectrometry (MS) we demonstrate that the oxygenation of hemoglobin 
(Hb) provides a dramatic example of a type 2 scenario. The observed behavior is consistent 
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with cooperative T → R switching, where part of the intrinsic O2 binding energy is 
reinvested for destabilizing the ground state. This destabilization increases the Boltzmann 
occupancy of unfolded conformers, thereby enhancing HDX rates. Surprisingly, O2 binding 
to myoglobin (Mb) also induces elevated HDX rates. These Mb data reveal that type 2 
behavior is not limited to cooperative multi-subunit systems. Although enhanced protection 
from deuteration is widely considered to be a hallmark of protein-ligand interactions, this 
work establishes that an overall deuteration increase also represents a viable outcome. HDX-
based ligand screening assays, therefore, have to allow for canonical as well as non-canonical 
effects. 
Numerous biological processes and drug action mechanisms are mediated by noncovalent 
protein-ligand binding. The affinity of these interactions ranges from millimolar to sub-
picomolar Kd values, with dissociation free energies that are given by ∆dG° = -RT ln Kd. For a 
protein P and its ligand L the dissociation constant is defined as Kd = [P][L]/[PL]. The 
magnitude of ∆dG° is governed by a complex interplay of entropic and enthalpic factors, with 
contributions originating from the protein, the ligand, and the solvent.1-3 Methods for 
predicting protein-ligand affinities are still in their infancy,4-5 largely because enthalpy-
entropy compensation effects and related issues remain poorly understood.6-11  
 Isothermal titration calorimetry (ITC) is widely used for exploring thermodynamic 
aspects of protein-ligand interactions.2 Binding can also be explored in titration studies with 
optical, NMR,12 or mass spectrometric detection.13-14 Nonetheless, there remains a need for 
improved strategies that are capable of probing thermodynamic and structural aspects of 
protein-ligand systems. Areas that will benefit from such initiatives include the screening of 
drug candidates, as well as epitope mapping applications.15-16 
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 Hydrogen/deuterium exchange measurements (HDX) with mass spectrometry (MS)17-
22
 or nuclear magnetic resonance (NMR) spectroscopic detection23-32 have gained a strong 
foothold for protein-ligand binding studies. Exposure of a protein to a D2O-based solvent 
induces the replacement of backbone amide hydrogens with deuterium. Most backbone N-H 
groups in natively folded proteins are engaged in hydrogen bonds. Deuteration at these sites 
is mediated by thermally activated opening/closing fluctuations that transiently rupture 
hydrogen bonds and expose N-H groups to the solvent.33 The exchange mechanism can be 
expressed as34 
 
 
    (3.1) 
 
 
where the opening and closing rate constants are designated as kop and kcl, respectively, and 
where kch is the chemical rate constant.35 
HDX experiments are generally conducted with the expectation that ligand binding 
will induce a reduction in deuteration rates, a view that is based on a large body of prior 
MS17-22 and NMR23-32 work. This widely held paradigm implies that ligand-bound systems 
will tend to be “more tightly folded”, and hence more resilient towards structural fluctuations 
of the type described in eq 2.1. A multitude of protein-ligand systems behave in accordance 
with this canonical scenario,17-20,22-32,36-37 consistent with the fact that intermolecular binding 
is often accompanied by the formation or the strengthening of intramolecular bonds.38-39 In 
favorable cases this ligand-induced HDX protection is most pronounced for regions that 
directly interact with the ligand. However, this is not always the case,40-41 e.g., when the 
binding mechanism involves allosteric elements.17-18,26,42   
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Interestingly, it appears that ligand binding can have stabilizing as well as 
destabilizing effects on the protein structure.43 For example, there are instances where ligand 
binding decreases deuteration rates only in some regions of the protein, whereas other 
regions display more extensive HDX.42,44-46 Related differential effects have been reported on 
the basis of neutron scattering experiments,47 computer simulations,48 and NMR spin 
relaxation measurements.3,9 J-coupling experiments have highlighted the possibility that 
ligand binding can induce a buildup of strain in some regions of a protein, evident from an 
elongation of certain backbone hydrogen-bonds.49 
The preceding considerations call into question the view that protein-ligand 
interactions are generally associated with reduced deuteration rates. The current work goes 
one step further, and asks if it is possible that ligand binding can sometimes cause an overall 
HDX acceleration. We show that such a scenario is indeed feasible. Using hemoglobin (Hb) 
and myoglobin (Mb) as examples, we illustrate the entire range of possible outcomes – from 
strongly reduced (“type 1”) to strongly increased deuteration rates (“type 2”). We propose a 
model that links the different types of ligand binding effects to alterations in the Boltzmann 
occupancy of partially unfolded conformers. 
 
3.2.   Materials and Methods 
3.2.1. Proteins and Reagents.  
Horse heart met-(FeIII)-Mb and sodium dithionite (NaS2O4) were purchased from Sigma (St. 
Louis, MO). Na2HPO4, NaH2PO4, and NaCl were from Caledon (Georgetown, ON, Canada), 
and D2O was procured from Cambridge Isotope Laboratories (Andover, MA). Protein 
solutions for all experiments contained 50 mM phosphate buffer, as well as 20 mM NaCl or  
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10 mM sodium dithionite. Apo-Mb was prepared using butanone extraction.50 Deoxy-(FeII)-
Mb was prepared by exposing met-Mb to 10 mM dithionite under nitrogen at neutral pH.51 
Deoxy-Mb was then converted to oxy-Mb by the introduction of air followed by dithionite 
removal on a G-25 Sephadex size exclusion column (Sigma) that was eluted with 10 mM 
aqueous ammonium acetate. Subsequently, the protein was dialyzed against 50 mM 
phosphate buffer containing 20 mM NaCl. Oxy-Hb was isolated from fresh bovine blood as 
described previously.52 Deoxy-Hb was prepared by exposing oxy-Hb to 10 mM sodium 
dithionite and deoxygenation under nitrogen.53 UV-Vis absorption spectra were recorded on 
a Cary 100 instrument (Varian, Mississauga, ON, Canada). The different heme oxidation and 
ligation states produced by the procedures outlined above give rise to characteristic UV-Vis 
absorption spectra that are consistent with reference data from the literature (Figure 3-1).54 
pH values were measured using a Fisher (Waltham, MA) AB15 pH meter, these values are 
reported without isotope correction. 
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Figure 3-1: (a) UV-Vis absorption spectra of different Mb derivatives (oxy, deoxy, and met) 
at pH 7. (b) UV-Vis spectra of oxy- and deoxy-Hb. Also shown in both panels are spectra of 
the deoxy proteins after 2h of HDX with repeated removal of aliquots. 
 
3.2.2. Hydrogen/Deuterium Exchange Mass Spectrometry.  
50 µM protein (in the apo, oxy or deoxy states) in 50 mM sodium phosphate buffer 
containing 20 mM NaCl or 10 mM sodium dithionite was mixed with 9 volumes of D2O 
containing the same buffer and salt concentrations as the stock, resulting in a protein 
concentration of 5 µM with a measured pH of 7.2 at room temperature (22 °C). 30 µL 
aliquots were removed at various time points ranging from 1 to 120 minutes after initiation of 
labeling. UV-Vis experiments confirmed that the deoxy-samples remained de-oxygenated 
throughout the experiment (Figure 3-1). The aliquots were quenched at pH 2.4 by addition of 
HCl on ice, followed by flash freezing in liquid nitrogen and storage at -80 °C. The aliquots 
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were rapidly thawed to ~0 °C and manually injected into a nanoACQUITY UPLC with HDX 
technology (Waters, Milford, MA)55 for desalting and peptide separation within 15 min on an 
equilibrated reversed phase column (BEH C18 1.7 µm, 1 mm × 100 mm) using a 
water/acetonitrile gradient in the presence of 0.1% formic acid at 35 µL min-1. Online 
digestion was performed using a POROS pepsin column (2.1 mm × 30 mm) from Life 
Technologies/Applied Biosystems (Carlsbad, CA) at 15 °C. The temperature for peptide 
trapping and reversed phase separation was set to 0 °C. Blank (water) injections were 
performed in-between protein injections to eliminate carryover. Peptide mass analysis was 
performed on a Waters Synapt HDMS instrument with source and desolvation temperatures 
of 80 and 300 °C, respectively, a cone voltage of 30 V, and an electrospray voltage of 2.8 
kV. The identity of each peptide was confirmed by tandem MS based on the known 
sequences (Figure 3-2 and 3-3). 
 
Figure 3-2: Peptic cleavage map of Mb. Solid lines represent peptides used for data analysis, 
and dashed lines represent redundant fragments. Helices are indicated by boxes 
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Figure 3-3: Sequence of the Hb α and β subunits. Solid lines represent peptides used for data 
analysis, and dashed lines represent redundant fragments. Helices are indicated by boxes. 
 
 Zero time point controls (m0) for the correction of artifactual in-exchange were 
performed by exposing the proteins to premixed D2O and quenching buffer, using the 
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solutions described above. Fully exchanged control samples (m100, for the correction of 
artifactual back exchange) were prepared by incubating 5 µM protein in labeling solution at 
pH 2.4 for 9 h (Hb) or 48 h (Mb). For measuring HDX kinetic profiles the centroid mass of 
all peptides as a function of labeling time was determined using HX-Express(Figure 3-4 and 
3-5).56  
 
 
 
 
 
 
 
 
 
 
Figure 3-4: HDX kinetics of peptides covering the sequence of Mb showing deoxy-Mb 
(open black circles) and oxy-Mb (filled circles). Residue numbers of the individual peptides 
are indicated in each panel. Also shown are data acquired for apo-Mb (filled red triangles). 
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Figure 3-5: HDX kinetics of peptides covering the α and β subunits of oxy-Hb (filled 
symbols) and deoxy-Hb (open symbols). Residue numbers are indicated in each panel. Lines 
are biexponential fits. 
 
The resulting data are reported as % Deuteration = (m-m0)/(m100-m0). Intact protein 
HDX/MS was conducted without using the integrated HDX module. Protein separation was 
performed on a C4 column (BEH300 C4 1.7 µm, 2.1 mm × 50 mm) at a flow rate of 200 µL 
min-1. The injection loop volume was 20 µL and the total amount of protein per injection was 
100 pmol. The injection syringe, column, injector and solvent delivery lines were kept at 0 
°C in an ice bath. All measurements were conducted in triplicate; error bars represent 
standard deviations. 
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3.3.      Results and Discussion 
3.3.1. Thermodynamic Considerations.  
Prior to discussing experimental data, it is necessary to examine the connection 
between ligand binding and HDX kinetics. Under EX2 conditions  
(kcl >> kch) the deuteration rate constant kHDX of a backbone N-H within the framework of eq 
2.1 can be expressed as 
 
    kHDX = pop kch                   (3.2) 
 
where pop is the fraction of time that the site spends in the open state.33 A lowering of kHDX 
does not necessarily imply that the protein becomes “more rigid” in the sense that it loses 
conformational entropy, has less extensive RMS fluctuations, or slows down its closed ↔ 
open interconversion. Instead, according to eq 2 the only unambiguous conclusion that can 
be drawn from a reduced EX2 rate is that amides spend less time in the open state. 
Using Boltzmann statistics,57 pop can be calculated according to 
 
             (3.3) 
where ∆opG° is the opening free energy and Z = 1 + exp(-∆opG°/RT) is the partition 
function.58 For a stable protein kcl >> kop, such that ∆opG° >> 0 and Z ≈ 1. [ Note that One can 
define an opening equilibrium constant Kop = exp(-∆opG°/RT), such that eq 2.2 turns into the 
well-known expression kHDX = Kop kch. For interpreting protein-ligand interactions it is 
advantageous to use an alternative approach that retains the exponential notation of eq 2.3.] 
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The occupancy of the closed state is 1/Z ≈ 1. When expressing free energy in RT units (∆opG° 
= ∆j × RT) the excited state occupancy becomes pop = exp(-∆j) such that 
 
    kHDX = e - ∆j kch            (3.4) 
 
We will first discuss ligand binding effects for a hypothetical two-state protein that 
undergoes conformational fluctuations between its native (N) and unfolded conformation 
(U). This textbook approach (Figure 3.6)22,59 envisions that N can form a complex NL, 
whereas U is incapable of ligand binding. Opening/closing transitions (eq 1) are equivalent to 
global unfolding/refolding for this two-state system. We arbitrarily assume that in the 
absence of ligand ∆opG° = 4 RT, such that pop = e-4 (Figure 3-6A). Figure 3-6B illustrates 
what happens when ligand binding lowers the standard free energy of the ground state by 
∆dG° = 2 RT. This widening of the free energy gap changes pop from e-4 to e-6, thereby 
reducing kHDX (eq 2.4). This example demonstrates that alterations of excited state 
occupancies are key to understanding ligand binding effects in HDX studies. 
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Figure 3-6: Free energy level diagram of a two-state protein that can bind a ligand L in the 
ground state only. (A) No ligand present. U (open) is separated from the ground state N 
(closed) by 4 RT, resulting in an excited state occupancy of e-4. (B) Ligand binding widens 
the gap between U and the new ground state NL to 6 RT. The excited state occupancy drops 
to e-6 and kHDX decreases according to eq 3.4. 
 
Unfortunately, the two-state model of Figure 3-6 represents an oversimplification 
(except for special cases33). Under realistic conditions the opening/closing dynamics of 
proteins are dominated by a multitude of sub-global events such as foldon fluctuations, 
fraying, and local dynamics down to the individual amide level.33,36,60-61 Most of these 
spatially confined events can proceed without dissociation of the PL complex. It is not 
obvious, therefore, why ligand binding should always widen the free energy gaps between 
the ground state and partially unfolded conformers. In other words, it seems unjustified to 
expect that binding will generally decrease kHDX. A closer examination of this issue requires a 
refined model.  
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Figure 3-7: Free energy level diagram of a protein that can adopt many partially unfolded 
ligand-bound states. Only three of these are shown. The Boltzmann occupancy of each state 
is exp(-∆j). Ligand binding lowers the free energy of the ground state by ∆dG°. (A) No ligand 
present. Excited states are assumed to be ∆j = 5, 7, and 9 RT units above the ground state; (B) 
Type 1 scenario, where ligand binding lowers HDX rates. Excited state populations are 
reduced relative to (A), and kHDX decreases. (C) Type 0 scenario, where excited state 
populations and HDX kinetics remain unchanged after binding. (D) Type 2 scenario, where 
excited state populations are increased such that deuteration proceeds more rapidly after 
binding. The overall binding affinity in (D) is determined by two competing contributions (eq 
3.5). 
 
 Figure 3-7A schematically illustrates the many thermally excited states that are 
accessible to a ligand-free protein under native solvent conditions. Each of these excited 
levels (only three are shown to prevent clutter) represents a conformation where a certain 
subset of amides is open, whereas the ground state N is all-closed. The occupancy of each 
level is given by eq 3.3, with the caveat that the partition function now becomes Z = 1 + Σ 
exp(-∆j) where the sum extends over all possible conformers. Nonetheless, the 
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approximation Z ≈ 1 still holds because kcl >> kop.23,24 This implies that the occupancy of 
each excited state can still be expressed as p = exp(-∆j), and that eq3.4 remains valid. Ligand 
binding will shift the free energy levels of the ground state, as well as those of the partially 
open conformers. We will have a look at three conceivable types of outcomes, all of which 
are scaled such that the NL ground state corresponds to ∆j = 0. 
Type 1: Ligand binding lowers the free energy of NL by ∆dG° (chosen to be 4 RT in 
Figure 3-7B). Protein-ligand contacts cause a strengthening of intramolecular bonds via 
entropic cooperativity and local concentration effects.59 As a consequence, transitions to 
excited conformers are associated with wider free energy gaps (larger ∆j values) than in the 
absence of ligand. The lower occupancy of partially unfolded conformers causes a decrease 
of HDX rates, as dictated by eq 3.4. 
Type 0: A ligand binds with the same affinity as in the previous case (∆dG° = 4 RT), 
but in a fashion that has only very minor effects on the internal energy landscape of the 
protein. For example, the ligand might interact with a solvent-exposed side chain.62 In this 
case all of the excited conformations will shift down by the same amount ∆dG° as the NL 
ground state. The ∆j values under these conditions will remain the same as for the ligand-free 
case. Hence, ligand binding will cause no change in the HDX kinetics (Figure 3-7C). 
Type 2: We consider a protein with a binding site that possesses a large intrinsic 
affinity ∆dG°intr. However, the ligand can only be accommodated in the NL ground state after 
an unfavorable structural change has taken place. This conformational switching event is 
associated with a free energy “penalty” termed ∆G°switch. The overall binding affinity in this 
scenario is the sum of two opposing contributions. 
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 ∆dG° = |∆dG°intr| - |∆G°switch|   (3.5) 
 
The NL ground state remains thermodynamically favored as long as ∆dG° > 0. Ligand-
induced distortion of the protein implies that conformers with open N-H sites are more 
readily accessible than in the absence of L. Thus, ligand binding lowers ∆j values, resulting 
in increased HDX rates throughout the protein (eq 3.4, Figure 3-7D). 
 The countless published examples17-20,22-32,36-37 of HDX rate reduction following 
ligand binding demonstrate that Type 1 interactions represent by far the most common 
scenario. Reports of Type 0 behavior are more scarce, although the use of HDX/MS for 
verifying the absence of perturbations in antibody-drug conjugates is relevant in this 
context.63 Type 2 behavior has been rarely, if ever, discussed. It remains unclear if (and 
under what conditions) the occurrence of globally accelerated HDX kinetics after ligand 
binding is a realistic scenario. 
 
3.3.2. Oxygenation of Hemoglobin: Type 2 Binding.  
Hb consists of two symmetric heterodimers, α1β1 and α2β2. The helical subunits within 
each dimer interact closely with one another, whereas contacts across the α1β1/α2β2 
interfaces are less extensive.64 Each subunit can bind O2 at its Fe(2+) heme. The cooperative 
deoxy (T) → oxy (R) transition has been explored in great detail.54,65-68 Oxygenation causes a 
~15° rotation of α1β1 relative to α2β2,65-66 thereby disrupting salt bridges between the 
Lys40(α1/2) side chains and the β2/1 C-termini.67 Other α1β1/α2β2 contacts are weakened 
as well. The structural distortion upon O2 binding carries a significant free energy penalty 
∆G°switch,68-70 making Hb a likely candidate for a type 2 scenario. 
 81 
 
 
 
Figure 3-8: HDX kinetics of deoxy-Hb (open symbols) and oxy-Hb (filled symbols). The 
two panels show data for the intact α (A) and β subunits (B) of the tetramer. Solid lines are 
biexponential fits. 
 
 HDX/MS experiments on deoxy- and oxy-Hb were conducted in neutral solution. 
Intact subunit measurements reveal that deuteration is greatly elevated for oxy-Hb compared 
to deoxy-Hb. When averaged over the 2 h experimental time window, the deuteration 
increase for α- and β-globin after oxygenation is about 15% and 20%, respectively (Figure 3-
8). These data reveal that Hb indeed represents a type 2 binder. Our findings are consistent 
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with earlier tritium labeling and HDX work.71-72 However, those studies did not discuss the 
unusual nature of Hb-O2 interactions, which are different from the type 1 binding behavior 
seen for most other proteins.17-20,22,36-37 
 
Spatially-resolved HDX data were obtained using pepsin digestion and LC-MS. The 
resulting peptide deuteration kinetics reflect the opening/closing dynamics exhibited by 
individual Hb regions (Figures 3-3, 3-5). Deuteration percentages for t = 60 min were 
mapped onto Hb crystal structures (Figure 3-9A, B). Segments in the interior of the tetramer 
tend to be strongly protected (e.g., the center portions of helices G and H in both subunits, 
Figure 3-9A, B, blue). Peripheral elements such as helices αA and βA exchange quite rapidly 
(Figure 3-9B, red). The difference map of Figure 3-9C highlights the changes in deuteration 
after oxygen binding. More extensive HDX takes place predominantly for elements that 
contact the α1β1/α2β2 interfaces. Large deuteration increases are also seen for α87-98 and 
β91-101 (Figure 3-5, Figure 3-9C, red). These two peptides comprise the proximal iron 
ligands αHis87 and βHis91 which play a key role for transmitting movements of the iron 
centers to the F helices.67 Thus, protein elements that directly participate in cooperative T → 
R switching are those for which type 2 behavior is most pronounced. 
The type 2 behavior of Hb reflects free energy partitioning upon oxygenation, 
consistent with the model put forward in Figure 3-7D and eq 3.5. The intrinsic O2 binding 
free energy is ∆dG°intr = 34 kJ mol-1 heme-1 when averaged over all four binding steps from 
the deoxy-T to oxy-R.68 This intrinsic contribution arises from interactions of O2 with the 
Fe(2+) center and hydrogen bonding with the distal His of helix E.73 A significant fraction of 
this free energy (∆G°switch = 7 kJ mol-1 heme-1) is used up for T → R switching of the protein 
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scaffold,68 thereby destabilizing the ground state structure and enhancing HDX kinetics as 
dictated by eq 3.4. The resulting overall O2 binding affinity is ∆dG° = 34 – 7 = 27 kJ mol-1 
heme-1 (eq 3.5).68 
On the basis of these Hb data it is tempting to speculate that type 2 HDX might be 
limited to cooperative multi-subunit systems. Interestingly, the observations discussed below 
reveal that this is not the case. 
 
3.3.3. Type 2 Oxygen Binding to Myoglobin.  
Mb is a monomeric protein with a fold very similar to that of α- and β-globin.74 Mb-O2 
interactions are virtually identical to those in Hb, involving a Fe(2+) heme and a distal His.54 
However, protein structural changes upon Mb oxygenation are much less extensive than for 
Hb.74 The average RMS displacement after O2 binding is only 0.2 Å for Mb, whereas that of 
Hb is 1.1 Å.75 Due to the lack of subunit cooperativity Mb exhibits a hyperbolic O2 binding 
profile, while the Hb oxygenation curve is sigmoidal.76 Thus, Mb represents an ideal model 
system for scrutinizing possible linkages between binding cooperativity and type 2 behavior.  
Intact protein data reveal that oxy-Mb shows more extensive HDX than deoxy-Mb (Figure 3-
10). The deuteration enhancement is roughly one third of that seen for Hb (Figure 3-8). 
Nonetheless, Figure 3-10 clearly demonstrates that O2 binding to Mb also represents a type 2 
scenario. In other words, type 2 effects are not limited to proteins with multi-subunit 
cooperativity.  
Spatially-resolved HDX/MS measurements for Mb (Figure 3-2, 3-4) reveal extensive 
structural dynamics in the N-terminus, and in the B/C/D loop region (Figure 3-11A, B). O2 
binding significantly increases HDX levels in helices A and H (Figure 3-11C, red), 
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resembling the behavior seen for Hb (Figure 3-9C). In addition, oxygenated Mb shows 
strongly enhanced deuteration in helix E (Figure 3-11C, red) which participates in ligand 
binding via the distal His64. This accelerated deuteration of helix E is somewhat different 
from the behavior seen for Hb, where HDX enhancements are more pronounced on the 
proximal side of the heme (helix βF, Figure 3-9C). 
 
 
 
 
 
 
 
 
 
 
 
 85 
 
 
Figure 3-9: Spatially-resolved deuteration pattern of (A) deoxy-Hb and (B) oxy-Hb for t = 
60 min (PDB files 1HDA77 and 2QSS78). Complete time profiles are shown in Figure S3. (C) 
HDX difference map averaged over the 2h experimental time window; red represents 
segments that show most strongly elevated deuteration after O2 binding. 
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 The observation of type 2 behavior for Mb suggests that O2 binding to this protein is 
also  
associated with a free energy penalty ∆G°switch (eq 3.5). However, this ∆G°switch must be 
smaller than the corresponding Hb value (less than 7 kJ mol-1),68-69 as implied by two 
observations: (1) deuteration enhancements are less pronounced for Mb than for Hb (Figures 
2.3, 2.5). (2) Although ∆dG°intr is virtually identical for the two proteins, the overall O2 
binding affinity of Mb (∆dG° = 35 kJ mol-1)73 is larger than that of Hb (27 kJ mol-1 heme-1).68 
In the case of Hb it is clear that ∆G°switch is dissipated via the disruption of protein-protein 
contacts during T → R switching.68 In the case of Mb the fate of this free energy contribution 
is not as clear. Our observations, as well as existing X-ray data74-75 are consistent with the 
view that oxygenation-induced local changes on the heme build up conformational strain in 
the protein. The Mb elements affected by this phenomenon display elevated deuteration rates 
as a result of their increased pop values (red in Figure 3-11C). 
 
3.3.4. Heme Binding to Apo-Myoglobin: A Type 1 Event.  
Heme binding to apo-Mb results in significant stabilization of the protein. This transition has 
been studied extensively,79-80 but we include it here for completeness as an example of a type 
1 scenario. Heme makes numerous contacts within the hydrophobic binding pocket of the 
protein, in addition to iron ligation by the proximal His93 in helix F.81 
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Figure 3-10: Intact protein HDX kinetics of holo-Mb in the oxy-state (filled symbols) and in 
the deoxy-state (open symbols). Also included are data for the heme-free protein (apo-Mb, 
red). 
 
 
Heme-bound Mb exhibits dramatically lower deuteration values than the apo-state (Figure 3-
10). Spatially resolved measurements (Figure 3-2) show that this stabilization affects all 
regions of the protein (Figure 3-12A, B). The largest changes are seen around helix F (Figure 
3-2) which adopts a well-defined structure only in the presence of heme.79 The type 1 
character of the apo-Mb → holo-Mb transition is readily apparent from the HDX difference 
map of Figure 3-12C which is completely blue. This has to be contrasted with the red 
difference maps that apply to the oxygenation events discussed above (type 2 behavior, 
Figure 3-9C, 3-11C). 
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Figure 3-11: Spatially-resolved deuteration pattern of (A) deoxy-Mb and (B) oxy-Mb for t = 
60 min (PDB files 2V1K82 and 1DWR83). Complete time profiles are shown in Figure S5. 
(C) HDX difference map averaged over the 2h experimental time window; red represents 
segments that show most strongly elevated deuteration after O2 binding. 
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Figure 3-12: Spatially-resolved deuteration pattern of (A) apo-Mb and (B) oxy-Mb for t = 60 
min. PDB file 1DWR83 was used for both panels because high resolution X-ray data for apo-
Mb are not available. (C) Difference map averaged over the 2h experimental time window; 
regions that show less extensive HDX in the presence of heme are highlighted in dark blue. 
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3.4.  Conclusions 
This work demonstrates that protein-ligand interactions can result in a wide range of HDX 
signatures. Binding can cause a global decrease of deuteration rates (type 1), or it may cause 
accelerated deuteration (type 2). Both of these extremes are thermodynamically feasible 
because the ensemble-averaged behavior of a protein is dominated by the ground state. 
Binding is a spontaneous process as long as the free energy of NL is lower than that of N 
(Figure 3-7). This criterion for spontaneity is irrespective of the excited state behavior, 
because the cumulative Boltzmann occupancy of the corresponding conformers is low.33 
Nonetheless, it is these sparsely populated open states that govern the HDX properties of the 
protein according to eqs 3.1, 3.4. The largely unpredictable ligand-induced changes of ∆j 
values translate into a range of possible deuteration scenarios (Figure 3-7). Type 1 and 2 
scenarios are both compatible with either induced fit or conformational selection modes of 
binding, whereas type 0 behavior may be more appropriately described as a lock-and-key 
interaction.84-85 
 The observation of type 2 behavior is, perhaps, not so surprising in the case of Hb due 
to the known interplay between ∆G°switch and ∆dG°intr which is a common feature of 
cooperative multi-subunit proteins (Figure 3-7D).68 However, the observation that 
oxygenation of Mb also represents a type 2 transition demonstrates that ligand-induced 
deuteration enhancements are not limited to cooperative systems with multiple binding sites. 
 The cartoon representation of Figure 3-7 depicts just three conceivable scenarios that 
might be encountered upon ligand binding. Other cases are certainly possible. For example, 
data consistent with mixed type 1/0/2 scenarios have been reported.42,44-46 Also, individual 
amide N-H groups do not have to remain associated with a certain type of opening event. 
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Ligand-induced changes of the protein energy landscape may cause N-H sites to move within 
the excited state manifold, e.g., from a low level in Figure 3-7A to a higher one in Figure 3-
7B. Such differential free energy shifts provide an opportunity for binding site mapping, 
keeping in mind that allosteric effects have to be considered for this type of experiment.17-
18,42
 
 The prevalence of type 1 binding in the literature tends to foster the view that reduced 
deuteration rates are a general hallmark of protein-ligand interactions.17-20,22-32,36-37 Our 
findings demonstrate that it is easy to overlook biologically important interactions when 
using screening approaches that exclusively focus on such type 1 scenarios. The observation 
of type 2 behavior for two of the most “mundane” protein-ligand complexes (Hb-O2 and Mb-
O2) suggests that non-canonical HDX scenarios may be more common than currently 
thought. In any case, practitioners have to be aware that biological interactions in different 
proteins may elicit very different types of HDX responses. 
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Chapter 4. Activation of ClpP Protease by ADEP Antibiotics: 
Insights from Hydrogen Exchange Mass Spectrometry 
 
4.1. Introduction 
The ability to degrade damaged or misfolded proteins is a prerequisite for maintaining a 
healthy intracellular milieu.1 In eukaryotic cells the dominant non-lysosomal degradation 
pathway proceeds via the ubiquitin-proteasome system.2 Prokaryotes3 and mitochondria4 
mainly rely on members of the caseinolytic protease (Clp) family for ATP-dependent 
degradation. ClpP is a member of this family that was initially discovered in Escherichia 
coli,5 and that has become a paradigm for proteolytic degradation complexes in general.3,6-8 
 In ClpP fourteen identical subunits assemble into two stacked heptameric rings, 
forming a 300 kDa barrel. The hydrolytically active sites are located inside a central chamber 
that can be accessed via two axial pores.6-7,9-15 Each of the subunits consists of an N-terminal 
region, a globular head domain, and a handle (Figure 4-1a-c).13,16 Contacts between the two 
heptameric rings are mediated by intercalation of the handles from alternating subunits.16 
ClpP by itself cannot hydrolyze large substrates because the axial pores are blocked by the 
N-terminal regions of the seven subunits at both ends of the barrel (Fig. 4-1c).6-7,15,17-18 
 An active degradation complex that is capable of degrading full-length proteins is 
formed when ClpP binds to AAA+ proteins such as ClpX or ClpA.3,6,19 These AAA+ proteins 
are ATP-dependent unfoldases that form hexameric rings. They interact with ClpP  
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,  
Figure 4-1: X-ray structural data for E. coli ClpP. (a) ClpP monomer in the absence of 
ADEP1. N-terminal region, head and handle regions are indicated. Residues 1-18 are 
highlighted in red, the active site nucleophile S97 is shown in orange. (b) Equatorial and (c) 
axial view of the ADEP1-free ClpP 14mer (pdb file 1YG6).9 (d) Single monomer, (e) 
equatorial view, and (f) axial view of ClpP bound to ADEP1 (pdb file 3MT6).14 ADEP1 
molecules are highlighted in magenta. Arrows in (e) highlight a slight dilation of the apical 
(head) regions upon ADEP1 binding, as well as a subtle contraction in the equatorial plane.14 
 
 
via insertion of hydrophobic loops into nonpolar clefts. These clefts are located between 
adjacent ClpP subunits, surrounding the axial pores. The function of AAA+ proteins is to 
recognize, bind, unfold, and translocate substrate proteins through the ClpP axial pores into 
the degradation chamber.3,6,20-22 It has not been possible thus far to obtain X-ray structures of 
intact ClpP/AAA+ complexes. Crystallization of these systems is complicated by the peculiar 
symmetry mismatch, where heptameric ClpP rings are stacked against hexameric AAA+ 
rings.6-7,9 Thus, many functional aspects of these degradation machines remain unclear. Cryo-
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electron microscopy (EM)22 revealed that binding to an AAA+ ring causes the corresponding 
ClpP axial pore to open up, implying major structural changes of the ClpP N-terminal 
regions. The open pore allows threading of unfolded substrates into the degradation chamber. 
Unfortunately, the limited structural resolution of cryo-EM does not provide detailed 
information on the nature of the pore opening transition.7 Another unresolved question 
concerns the mechanism of product release, which may proceed via the ClpP axial pores,13,23-
24
 or through openings that transiently form in the equatorial region.10,25-27 
 Acyldepsipeptides (ADEPs) are nonpolar antibacterial compounds.7 The parent 
substance (ADEP1) has a lactone core derived from five amino acids, and an aliphatic C7H9 
tail.15 ADEPs bind ClpP in the hydrophobic clefts that would normally interact with AAA+ 
proteins.7 Intriguingly, ADEP binding opens the ClpP axial pores (Figure 1d-f).6-7 This 
transition allows ClpP to degrade a range of loosely folded proteins with high efficiency, 
bypassing the requirement for AAA+ participation. The resulting uncontrolled proteolysis is 
responsible for the antibiotic activity of ADEPs.28-29 Staphylococcus aureus and other Gram-
positive bacteria are susceptible to these compounds.30 Gram-negative organisms are largely 
resistant because their outer membrane acts as protective barrier against ADEPs, and 
possibly because of the presence of specific efflux pumps.31 Similar to the ADEP-bound 
state, a constitutively active form of ClpP is obtained by deleting the first 14 N-terminal 
residues.32 
 Deciphering the nature of ADEP-induced structural changes is complicated by the 
fact that ClpP can crystallize in various conformations, pointing to a malleable structure that 
is sensitive to crystal packing effects.7,9-10,26 This is particularly true for the N-terminal 
regions which are key for gating the axial pores. Most of the available ClpP X-ray structures 
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provide incomplete information for the first 18 residues, suggesting considerable disorder 
and highly dynamic behavior. Nonetheless, it is clear that the N-terminal regions have a 
propensity to form loops or hairpins, with two strands termed β
-1 and β0.9-10,12-13,15,21,26-27 
Recent X-ray studies led to two competing models for the ADEP-induced activation 
of ClpP.7 According to one proposal,15 the closed-pore conformation has relatively structured 
N-termini that are stabilized by hydrophobic clustering. Pore opening by ADEP was 
attributed to switching of the termini to a more disordered state.15 This scenario has been 
questioned,7 because the N-terminal regions in the open state of ref.15 appear to be influenced 
by crystal packing. An alternative model14 envisions that ADEP binding triggers formation of 
an “open collar”, consisting of β
-1/β0 loops that are oriented parallel to the ClpP symmetry 
axis (Figs. 4-1d-f).14 Both models agree that ADEP binding causes a slight equatorial 
contraction, and a dilation of the axial regions (arrows in Fig. 4-1e).14-15 
X-ray crystallography and cryo-EM provide static ground state structures that do not 
directly reflect biomolecular dynamics in solution.7,33-34 For understanding protein behavior it 
is essential to perform complementary investigations that probe dynamic features in a 
physiologically relevant solvent environment. Relaxation dispersion NMR measurements 
represent one promising avenue,25,35 but their application remains limited to very few 
laboratories. Hydrogen/deuterium exchange (HDX) coupled with mass spectrometry (MS) is 
a more accessible method.36-44 Protein regions that are disordered and/or highly dynamic 
undergo rapid deuteration, whereas HDX in rigid segments is much slower. HDX rates 
primarily reflect the stability of amide backbone H-bonds, although solvent accessibility also 
plays a role.45 The deuteration behavior of individual segments can be monitored by 
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subjecting the protein to peptic digestion after incubation in a D2O-containing environment. 
This approach allows the tracking of time-dependent peptide mass shifts by MS.  
Here, we employ HDX/MS for probing changes in the structure and dynamics of 
ClpP upon activation by ADEP1. Ligand binding causes rigidification of the equatorial belt, 
whereas the head regions undergo a slight destabilization. ADEP1-mediated switching to the 
open-pore state causes surprisingly small changes in the HDX behavior of the N-terminal 
regions. Our data suggest that gating of the axial pores is mainly based on alterations in the 
packing of N-terminal nonpolar residues. Such a mechanism helps reconcile the two 
competing proposals of the activation process.7,14-15 To the best of our knowledge, this work 
represents the first HDX/MS study on the ADEP-mediated activation of ClpP. 
 
4.2. Materials and Methods 
4.2.1.  Materials 
HEPES and glycerol were from Sigma (St. Louis, MO, USA), and potassium chloride was 
from Caledon (Ontario, Canada). D2O was from Cambridge Isotope Laboratories (Andover, 
MA). Magnesium chloride was purchased from Merck (Darmstadt, Germany). All chemicals 
were used as received. E. coli ClpP was overexpressed and purified from transformed E. coli 
cells as described,46 and ADEP1 was purified from Streptomyces hawaiiensis fermentation 
broth following established procedures.14 
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4.2.2. Backbone Amide Hydrogen/Deuterium Exchange Mass 
Spectrometry  
The experiments started with 300 µM ClpP (on a monomer basis) in 10 mM magnesium 
chloride, 100 mM KCl, 25 mM HEPES, and 10% glycerol (pH 7.5). ADEP1-bound samples 
were prepared by adding 2 µL of ADEP1 in DMSO to 20 µL of ClpP solution, resulting in a 
five-fold molar excess of ligand. These mixtures were pre-equilibrated for 24 h at 4 °C. 
Deuteration was conducted at room temperature. HDX was initiated by addition of 9 volumes 
of D2O containing labeling buffer which had the same salt and glycerol concentration as the 
stock solution, for a final measured pH of 7.3. On the basis of previously measured 
dissociation constants,47 the fraction of bound protein under labeling conditions was 
estimated to be 99%. 30 µL aliquots were removed at various time points ranging from 1 to 
360 min after initiating of labeling. These aliquots were quenched at pH 2.4 by addition of 
HCl on ice, followed by flash freezing in liquid nitrogen and storage at -80 °C. For spatially-
resolved HDX/MS experiments, the aliquots were rapidly thawed to ~0 °C and manually 
injected into a nanoACQUITY UPLC with HDX technology (Waters, Milford, MA)48 for 
desalting and peptide separation within 15 min on an equilibrated reversed phase column 
(BEH C18 1.7 µm, 1 mm × 100 mm) using a water/acetonitrile gradient in the presence of 
0.1% formic acid at 40 µL min-1 . Online digestion was performed using a POROS pepsin 
column (2.1 mm × 30 mm) from Life Technologies/Applied Biosystems (Carlsbad, CA) at 
room temperature. The temperature for peptide trapping and reversed phase separation was 
set to 1 °C. Blank (water) injections were performed in-between protein injections to 
eliminate carryover. 
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Mass analysis of peptides was performed on a Waters Synapt HDMS instrument with 
source and desolvation temperatures of 80 and 300 °C, respectively, a cone voltage of 30 V, 
and an electrospray voltage of 3 kV. The identity of each peptide was confirmed by tandem 
MS based on the known ClpP sequence.9 Zero time point controls (m0) for the correction of 
artifactual in-exchange were performed by first exposing ClpP to quenching buffer, followed 
by brief D2O exposure, resulting in the same final solution composition as for all other 
samples. Controls for fully exchanged ClpP (m100, for the correction of back exchange) were 
prepared by incubating 30 µM ClpP in labeling solution at pH 2.0 for 24 h. Biolynx 4.1 
(Waters) and HX-Express49 were employed to analyze the centroid mass of all peptides as a 
function of labeling time. Deuteration levels were determined as  
 
     (4.1) 
 
Intact protein deuteration measurements were performed using a procedure similar to that 
described above, but without using the integrated Waters HDX module. Protein separation 
was achieved using a C4 column (Jupiter 5 µm Proteo, 50 mm × 1 mm; Phenomenex) 
coupled to a UPLC pump at a flow rate of 100 µL min-1 without pepsin digestion. The 
injection loop volume was 20 µL and the total amount of protein per injection was 600 pmol. 
The injection syringe, column, injector and solvent delivery lines were kept at 0 °C in an ice 
bath. All measurements were performed in triplicate. Error bars represent standard 
deviations. Average deuteration differences for Figs. 4-6e, f were calculated as  
 
 (4.2) 
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%Deuteration values were determined by using eq. 4.1. The sum extends over the N = 6 time 
points that were measured for each peptide. 
 
4.3. Results and Discussion 
4.3.1. Global HDX Kinetics 
As a first step to understand the interaction of ADEP1 with ClpP, deuteration measurements 
were conducted at the level of intact subunits. Backbone amide HDX/MS data were recorded 
for labeling times ranging from one minute to six hours (Figure 4-2). ADEP1-free ClpP 
reaches a deuteration level of almost 60% at the end of the experimental time window. 
ADEP1 binding causes a dramatic reduction in the extent of labeling, resulting in a 
deuteration level that is ~20% lower after 6 h. This reduced deuterium uptake points to a 
stabilization of the overall ClpP structure upon ligand binding, resulting in a state that (on 
average) is less dynamic. Qualitatively similar ligand-induced stabilization effects have 
previously been observed by HDX/MS for many other proteins.37,39,50-51 
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Figure 4-2: Global ClpP HDX/MS kinetics recorded in the absence (open symbols) and 
presence of ADEP1 (filled symbols). Lines represent biexponential fits. 
 
 
4.3.2. Spatially-Resolved HDX/MS Measurements 
A more detailed view of the ClpP conformational dynamics can be gained by analyzing the 
HDX kinetics in a spatially-resolved fashion. Peptic digestion yielded 32 peptides with 
signal-to-noise ratios that were adequate for deuteration measurements, with an overall 
sequence coverage of 95% (Figure 4-3). Even without detailed analyses, it can be seen that 
ADEP1 binding does not affect all ClpP regions in the same fashion (Figure 4-4). As 
expected from the intact protein data, many peptides exhibit reduced deuteration levels in the 
presence of ADEP1. Other peptides show virtually identical HDX behavior with and without 
ADEP1. Surprisingly, there are also some segments that show higher deuteration levels after 
ligand binding. These three scenarios are exemplified in Figure 4.4 for peptides 135-141, 50-
61 and 82-89. 
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Figure 4-3: Sequence of E. coli ClpP.9 Solid lines represent peptides used for HDX/MS data 
analyses, dashed lines represent redundant peptides. Secondary structure elements are 
indicated. Selected hydrophobic residues are highlighted, matching the color scheme used in 
Figs. 4-7b-d. 
 
 A summary of all peptide data is provided in the deuterium uptake curves of Figure 
4.5. For the following discussion we will focus on a subset of peptides that cover the ClpP  
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Figure 4-4: Unprocessed HDX/MS data for three ClpP peptic peptides recorded in the 
absence (red solid lines) and in the presence (black dotted lines) of ADEP1 for three HDX 
time points. 
 
sequence in an almost contiguous fashion (solid lines in Figure 4-3). The availability of 
redundant data is nonetheless important, because it provides an internal consistency control. 
It is reassuring that peptides representing similar protein regions exhibit comparable kinetics 
(e.g., 50-61/51-58, 61-71/62-71/62-75, 82-89/82-91, 142-152/143-149, 184-189/187-193 in 
Fig. 4-5).  
To facilitate the discussion of peptide-resolved HDX data, deuteration percentages 
were mapped onto the crystal structure of ClpP in the absence (Figure 4-6a, b) and presence 
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of ADEP1 (Figure 4-6c, d) for t = 60 min. The handle domain (α5 and β6’, residues 120 to 
152) shows the most dramatic changes upon binding. In the absence of ADEP1 this region is 
only  
 
Figure 4-5: HDX kinetics of peptides in free ClpP (open symbols) and after ADEP1 binding 
(filled symbols). Residue numbers are indicated in each panel. Lines are biexponential fits. 
Error bars represent standard deviations of triplicate measurements. 
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marginally protected (β6’ is red and α5 is yellow, Figure 4-6a, b). ADEP1 binding causes a 
major stabilization of the handle, particularly in the 135-152 range that covers much of α5 
(green, Figure 4-6c, d). β6’ gets stabilized as well (orange, Figure 4-6c, d). 
Ligand-induced changes in the head domain are more subtle. Many elements in this 
region show high protection with and without ADEP1 (blue, Fig. 6a-d), such as 24-31 (β1), 
43-48 (center of α2), and 103-119 (β5, parts of α4 and β6). As already noted, there are several 
peptides in the head region that show higher HDX levels after ADEP1 binding.  
 
 
Figure 4-6: Mapping of the of Figure 4-5 HDX/MS data to the X-ray structures of ClpP for t 
= 60 min, shown for single ClpP subunits (top row), and for complete tetradecamers (bottom 
row). Colors in (a) - (d) represent deuteration percentages, as defined in the legend. Gray 
elements in (a) - (d) were not covered by peptide mapping. In (c) selected elements are 
identified; note that only one of the two ADEP1 molecules that are in contact with the 
subunit is shown. Panels (e), (f): HDX difference map. Colored regions correspond to 
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|average difference| > 5% (eq. 4.2). Segments that exhibit elevated deuteration after ADEP1 
binding are depicted in red. Segments with reduced deuteration are shown in blue. All other 
regions are depicted in gray. 
 
This ligand-induced destabilization is particularly pronounced for 17-23 (α1) and 82-
91 (β3) which are part of the ADEP1 binding cleft (Figure 4-6c).14-15 The N-terminal region 
(including β
-1 and β0, red in Figs. 6a-d) is almost completely deuterated after 60 min, 
regardless of ADEP1 binding. 
An overview of the regions that undergo stabilization (blue) and destabilization (red) 
after addition of ADEP1 is provided in Figure 4-6e, f. This representation uses a 5% 
threshold, calculated as outlined in the Methods section. ADEP1-induced destabilization is 
restricted to the head regions of the ClpP tetradecamer, whereas elements that are most 
strongly stabilized by ADEP1 are found in the equatorial (handle) region. The resulting red-
blue-red pattern of Figure 4.6f bears a striking correlation with the ADEP1-induced domain 
movements that have been inferred from X-ray structural data (arrows in Figure 4-1d).14, 15 
Specifically, contraction of the equatorial belt is concomitant with enhanced HDX protection, 
i.e., a more stable H-bonding network in this region. Conversely, dilation of the apical barrel 
ends is accompanied by partial destabilization of the head domains. 
 
4.3.3. Allosteric Nature of ADEP1 Binding 
Ligand binding to a protein occurs spontaneously when the corresponding free energy 
change, ∆bindG°, is negative. This thermodynamic stabilization upon binding lowers the 
Boltzmann population of transiently populated excited conformers.52-53 The resulting 
decrease in amide deuteration provides the basis of typical HDX ligand binding assays.37,39,50-
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51
 In some cases ligand-induced stabilization is most pronounced in the direct vicinity of the 
binding site.37,54-57 Other systems show allosteric behavior, where the ligand affects regions 
that are remote from the site of interaction.37,57-59 
 Our HDX data reveal that the interaction of ADEP1 with ClpP causes both local 
changes and allosteric switching. Ligand binding in the apical region induces a major 
rigidification of the  equatorial region. This long-distance effect requires the transduction of 
allosteric signals over ~30 Å, from the ADEP1 binding clefts to the handle elements α5 and 
β6’. What makes the ClpP behavior quite unusual is the fact that ADEP1 destabilizes some 
protein elements close to the binding site. At first sight, this effect seems to contradict the 
tenet that binding always results in a thermodynamic stabilization.37,39,50-51 However, binding 
equilibria are not governed by local effects, but by the overall free energy change. ∆bindG° is 
the sum of many individual contributions, each of which can be stabilizing (< 0) or 
destabilizing (> 0). Binding is a spontaneous process as long as the former outweigh the 
latter. Evidently, this is the case for the system considered here.  
 
 
4.3.4. Implications for Product Release  
The highly dynamic behavior of the free ClpP equatorial region seen in our HDX 
experiments (Figure 4-6a, b) is consistent with earlier NMR work.25 Along with other 
observations,10,26-27 those NMR data were interpreted in favor of a model where free ClpP as 
well as ClpP/AAA+ complexes release hydrolysis products via transiently formed equatorial 
openings. The results seen here point in a different direction. The pronounced structural 
stabilization in the handle regions (Figure 4-6c-f) makes it unlikely that ADEP1-bound ClpP 
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undergoes large opening/closing fluctuations that would be required for the formation of 
transient equatorial cavities. Instead, our HDX data are consistent with a scenario where 
product release occurs via the axial pores, as suggested previously.13,23-24 In principle, the 
isotope exchange pattern of ADEP1-bound ClpP would also be compatible with the presence 
of rigid equatorial openings that could participate in  
 
 
 
 
Figure 4-7: (a) Initial 60 min HDX period for peptides 1-7 and 8-16. (b) Top view of the 
axial pore region for free ClpP (1YG6).9 Key nonpolar residues (I, L, V, F, M) are 
highlighted in color. The N-terminal region is shown only for the single subunit that adopts a 
“down” conformation in the pdb file.9 Possible L2 and V3 positions (not resolved in the X-
ray data) are indicated by circles. (c) Approximate location of the “hydrophobic plug” that 
will form by clustering of up to seven sets of L2/V3/M5/V6/I7 residues, when several N-
termini adopt similar “down” conformations. (d) Top view of the ADEP1-bound open state 
(3MT6).14 Highlighted residues correspond to those in (b), (c). In addition, R22 and K25 are 
shown in cyan (with δ-guanido and ε-amino groups omitted, as indicated in the text). Note 
how the outside of the hydrophobic ring is stabilized by interactions with the ADEP1 alkyl 
tails. 
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product release. Currently existing X-ray structures do not show any evidence of large 
equatorial openings.14-15 Given the highly malleable nature of ClpP, however, it is possible 
that those crystal structures do not properly reflect all aspects of the handle domain behavior 
in solution. 
4.3.5. N-Terminal Changes During ADEP1-Mediated Pore Opening 
The key N-terminal segments that are involved in gating of the axial pore are 1-7 (ALVP tail 
and first three residues of β
-1) and 8-16 (β-1, turn, β0). The nearby region 24-31 (β1) exhibits 
very low deuteration levels with and without ADEP1, suggesting that β1 provides a rigid base 
for gating movements of the N-terminus. Segment 17-23 (α1) serves as hinge between β1 and 
the N-terminal region. Conformational switching of the latter may be facilitated by a 
“softening” of α1, evident from its higher HDX levels after ADEP1 binding (red, Figure 4-
6e). 
Peptides 1-7 and 8-16 are among the most rapidly exchanging segments, both with 
and without ADEP1 (Figure 4-5, Figure 4-7a). This observation is consistent with earlier 
evidence of extensive N-terminal disorder.9-10,12-13,15,21,26-27,35 Yet, it is surprising that the 
ADEP1-mediated pore opening transition is not accompanied by larger changes in the N-
terminal HDX kinetics. Segment 8-16 shows almost no HDX protection, regardless of the 
presence of ADEP1. The crystal structure of ADEP1-bound ClpP shows H-bonding between 
β
-1 and β0.14 However, our data imply that in solution these contacts are in rapid N-H⋅⋅⋅O=C 
↔ N-H   O=C equilibrium, rendering the corresponding backbone hydrogens highly 
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susceptible to exchange. We attribute stabilization of the β
-1/β0 open collar conformation to 
factors other than H-bonding (outlined below). 
Compared to 8-16, peptide 1-7 shows more protection. Interestingly, HDX of 1-7 is 
faster after ADEP1 binding (Figure 4-7a, 4-6e). Because H-bonding in the β
-1/β0 region is 
negligible (see previous paragraph), the alterations in the HDX behavior of 1-7 must be due 
to solvent accessibility differences.45 In other words, segment 1-7 is less accessible in free 
ClpP than after ADEP1 binding. Hydrophobic clustering is the dominant contributor to 
solvent exclusion in proteins.60-61 Strikingly, segment 1-7 mainly consists of nonpolar 
residues. These and other key nonpolar moieties have been highlighted in Figure 4-3 and 
Figure 4-7 to facilitate the following discussion. 
As pointed out elsewhere,7,15 a likely N-terminal structure for the closed-pore state of 
free ClpP in solution is the “down“ conformation displayed by subunit C in pdb file 1YG6.9 
In this conformation M5, V6, and I7 are in the vicinity of the pore center. The first four 
residues are not resolved, but sequence dictates that L2 and V3 must be adjacent to M5, V6, 
and I7 (Figure 4-7b). All five of these amino acids are nonpolar.62 Having multiple N-termini 
adopt similar “down” orientations will place up to 7 × 5 = 35 nonpolar residues in direct 
proximity to each other. We propose that clustering of these nonpolar moieties will result in a 
“hydrophobic plug” that is stabilized by the surrounding nonpolar head residues (F17, L23, 
L24, L48, F49, L50 from each subunit, Figure 4-7b). Figure 4-7c highlights the fact that such 
a hydrophobic network will block the axial pores of free ClpP. In support of this scenario, 
earlier studies already noted extensive hydrophobic contacts in the N-terminal region of free 
ClpP.7,15 Also, mutations that lower the nonpolar character of the N-terminal region induce 
partial opening of the pore, 35,63 consistent with destabilization of the hydrophobic plug. 
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Why does ADEP1 binding open up the pore, and why does this transition increase the  
HDX levels of peptide 1-7? X-ray structure 3MT614 shows that the ADEP1-bound open 
collar state is devoid of an axial hydrophobic plug. Instead, the N-terminal residues L2, V3, 
M5, V6, I7 are in contact with a nonpolar interaction network comprising F17, L23, L24, 
L48, F49, L50 (Figure 4-7d). In the absence of firm H-bonds, we propose that this 
hydrophobic clustering is the key stabilizing factor of the β
-1/β0 loops in the open collar state. 
Importantly, all seven ADEP1 molecules point their C7H9 alkyl tails towards the nonpolar 
moieties that are located around the rim of the pore. Clearly, the open state is stabilized by 
hydrophobic interactions between nonpolar residues and the ADEP1 alkyl tails (Figure 4-7d). 
Formation of these interactions after ADEP1 binding seems to be a major factor for 
triggering the transition to the open collar conformation. In addition, the opening event may 
be facilitated by the slight dilation of the head domains that occurs as the ADEP1 molecules 
wedge themselves into the binding clefts (arrows in Fig. 4-1e). We propose that the 
accelerated HDX kinetics of peptide 1-7 in the open state reflect the enhanced solvent 
accessibility of L2/V3/M5/V6/I7 after ADEP1-mediated disruption of the hydrophobic plug. 
Interestingly, R22 and K25 participate in the closely packed nonpolar network of the 
open pore conformation (Figure 4-7d, cyan). It might seem surprising to see K and R 
participate in hydrophobic interactions, since both of these residues are charged. However, 
the charges are located at the end of nonpolar chains (CαH-CH2-CH2-CH2-CH2-, and CαH-
CH2-CH2-CH2-, respectively), giving both K and R amphiphilic character. It is well known 
that this architecture allows K and R to participate in hydrophobic packing, while at the same 
time exposing their charged end groups to the solvent at the protein surface.53,64 Such a 
scenario applies to the case of ADEP1-bound ClpP, as illustrated in Figure 4.7d (for clarity, 
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the solvent-exposed guanido and amino groups of R22 and K25 have been omitted in the 
Figure).  
 
4.4. Conclusions 
The interpretation of HDX measurements on protein-ligand systems is frequently guided by 
the expectation that structural stabilization effects will be most pronounced in the vicinity of 
the ligand, such that deuteration data can be used for binding site mapping.65 Indeed, there 
are many proteins that behave according to this canonical scenario.37,54-57 Unfortunately, such 
a simplistic “HDX footprinting” view is inadequate for systems that show allosteric 
behavior,37,57 i.e., where the ligand affects structure and dynamics in regions that are remote 
from the binding site.58-59 The ADEP1/ClpP system represents a case where a footprinting 
interpretation of HDX patterns is inadequate. A simplistic analysis of the measured HDX 
kinetics would erroneously suggest the equatorial region as ADEP1 binding site, because this 
is where deuteration changes are most pronounced.  
The HDX/MS data of this study complement previous work on the interaction of 
ClpP with ADEP antibiotics. Our observations strongly suggest that the ADEP1-mediated 
opening of the ClpP axial pores involves switching between two different modes of 
hydrophobic packing. In free ClpP the clustering of nonpolar N-terminal residues yields a 
hydrophobic plug that is centered around the symmetry axis of the barrel, blocking access to 
the degradation chamber. ADEP binding dissolves this central plug by providing new 
hydrophobic anchor points (the seven alkyl tails on the outside of the pore) that nonpolar 
residues can bind to. By acting as hydrophobic nucleation sites, the ADEP1 molecules trigger 
switching to a conformation that has all seven N-terminal regions sequestered away from the 
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centerline of the barrel, thereby opening up the pore. Simply speaking, this gating mechanism 
relies on the “hydrophobic pull” exerted by ADEP1, causing a radial movement of nonpolar 
residues towards the outside. 
Our view of the pore opening transition is consistent with X-ray structures of free9,15 
and ADEP1-bound ClpP14 (Figure 4-7b-d). The scenario envisioned here helps resolve some 
of the differences7 in the interpretation of earlier X-ray studies.14-15 This reconciliation 
comprises (i) acknowledging the crucial role of hydrophobic clustering in the closed state as 
noted in ref.15; and (ii) accepting that ADEP1 binding triggers the formation of an N-terminal 
open collar as suggested in ref.14 (Figure 4-1f, 4-7d). Our data imply that this collar is 
primarily stabilized by a network of hydrophobic moieties that comprises nonpolar side 
chains as well as the seven ADEP1 alkyl tails. Given the HDX evidence for the highly 
dynamic nature of the N-terminal regions, neither the hydrophobic plug in free ClpP, nor the 
collar formed after ADEP1 binding should be envisioned as static entities. 
In future work, it will be interesting to conduct HDX measurements on ClpP in 
complex with AAA+ unfoldases. The C7H9 alkyl tail of ADEP1 mimics the first residue in 
the IGF/L loops of ClpA and ClpX 14-15,28-31 These IGF/L loops are essential for the 
association of AAA+ proteins with ClpP.66 Therefore, the model proposed here for opening 
and stabilization of the ClpP axial pore by ADEP1 may be extendable to the ClpP 
interactions with AAA+ proteins. In the absence of high-resolution X-ray data for 
AAA+/ClpP complexes, HDX/MS might be able to prove or disprove such a proposal. Also, 
future investigations should explore whether the interaction of ClpP with ADEPs shows 
cooperative behavior, analogous to the T/R switching seen for hemoglobin and other 
proteins.67-69 
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Chapter 5. Noncovalent Binding of a Cyclic Peptide Inhibitor to 
the Peptidyl-Prolyl Isomerase Pin1 Explored by Hydrogen 
Exchange Mass Spectrometry 
 
5.1. Introduction 
 
Proteins owe their specific biological functions to unique three-dimensional structures. The 
native fold of each protein is determined by numerous side chain interactions, as well as main 
chain contacts, i.e., hydrogen bonds that stabilize α-helices and β-sheets.1 The partial double 
bond character of backbone Cα(CO)-(NH)Cα groups favors a coplanar arrangement of the six 
atoms adjacent to peptide linkages. Steric constraints dictate that the trans configuration is 
greatly preferred.2 One exception to this rule are X-Pro bonds (where X can be any non-
proline residue). The backbone-linked five-membered ring of Pro causes the cis and trans 
isomers of the corresponding peptide bond to be relatively close in free energy.3-4 As a result, 
the occurrence of cis X-Pro bonds in native proteins is quite high, on the order of 7%.5 The 
cis-trans isomerization of X-Pro bonds is nonetheless a slow process that is associated with 
an activation barrier on the order of 60 - 80 kJ mol-1.6-8 
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Figure 5-1: (A) Crystal structure of human Pin1 (PDB 3TCZ).9 Selected active site residues 
and secondary structure elements are highlighted. Hydrophobic residues are shown in blue, 
cationic side chains are highlighted in orange, and the active site Cys113 is depicted in pink. 
The WW domain is colored cyan. Not all of the Pin1 residues were resolved in the X-ray 
data, causing the appearance of a discontinuous chain. (B) Representative NMR structure of 
the Pin1 inhibitor [CRYPEVEIC] in the free (unbound) state.10 The square bracket notation is 
used to indicate the cyclic nature of the peptide. 
 
Peptidyl-prolyl isomerases (PPIases) catalyze the cis-trans conversion of X-Pro bonds.11 This 
group of enzymes comprises a number of well-known members such as cyclophilins and 
FK506-binding proteins.3 Of particular interest for the current work, Pin1 is a PPIase that 
exhibits high specificity towards substrates where proline is preceded by phosphoserine or 
phosphothreonine (pSer-Pro or pThr-Pro).3,12 Pin1 is involved in eukaryotic cell cycle 
regulation,13 and as such it is a promising anticancer target.14-17 The C-terminal domain of the 
largest subunit of RNA polymerase II is one of the primary Pin1 in vivo substrates, 
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highlighting the involvement of Pin1 in transcription regulation.9,18 The phosphorylation-
dependent substrate specificity of Pin1 is consistent with its central role in 
kinase/phosphatase mediated signaling pathways, many of which become deregulated in 
cancer.19-20 In addition, Pin1 appears to be involved in disease states related to ageing, viral 
infections, asthma, and Alzheimer’s disease.21-25 
 The 17.6 kDa amino acid sequence of Pin1 forms a N-terminal WW domain (residues 
1-39) and a C-terminal PPIase domain (residues 45-163, Figure 5-1A).9,12 The former 
consists of three antiparallel β strands (β1′ - β3′), whereas the latter has a mixed secondary 
structure comprising strands β1 - β4 and helices α1 - α4. The relatively close contacts seen 
between the two domains in X-ray structural data9,12 may not adequately reflect the 
properties of Pin1 in solution where the WW and PPIase domains appear to be more 
independent of one another.26 The reaction mechanism of Pin1 remains elusive, although 
Cys113 clearly represents one of the key active site residues.27-28 Leu122, Met130, and 
Phe134 form a hydrophobic binding pocket that accommodates the substrate proline, whereas 
the cationic side chains of Lys63, Arg68, and Arg69 interact with the negatively charged 
phosphate.12 While the catalytic function of Pin1 resides within the PPIase domain, the WW 
domain may represent the initial site of substrate recognition.26,29 
 The role of Pin1 as a potential drug target has sparked the development of custom-
designed inhibitors that compete for binding with the natural pSer/pThr-Pro substrates.9,30-37 
Inhibitors carrying phosphate groups can act as substrate mimics; however, a problem with 
this approach is the limited membrane permeability of phosphorylated compounds which 
compromises their therapeutic potential.35 Hence, the identification of non-phosphorylated 
Pin1 inhibitors remains an important goal. Peptide libraries are an interesting starting point 
for Pin1 inhibitor screening. Unfortunately, the loss of conformational entropy upon complex 
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formation tends to reduce the binding affinity of many peptides. A promising strategy to 
overcome this problem is the use of cyclic peptides that experience a lower entropic penalty 
upon noncovalent binding to the protein receptor.38 Liu et al.39 were the first to successfully 
employ such a strategy for the development of Pin1 inhibitors. Similarly, Duncan et al.10 
used phage display technology to identify the cyclic peptide [CRYPEVEIC] (square brackets 
are used to denote the cyclic structure) as a highly selective ligand for the Pin1 PPIase 
domain with a dissociation constant around 0.5 µM (Figure 5.1B). Cyclization of the peptide 
was achieved by disulfide formation of the two terminal -SH groups. NMR spectroscopy was 
successfully applied for elucidating the solution structure of free [CRYPEVEIC], but 
unfortunately conformational information obtained for the protein-ligand complex was 
extremely limited. Also, crystallization studies of the Pin1-[CRYPEVEIC] complex have 
been unsuccessful to date.10 
 Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) is a widely used 
approach for examining protein structure, dynamics, and interactions.40-51 Solvent-exposed 
N-H sites in unstructured regions undergo deuteration with rate constants on the order of 1 s-
1
.
52
 Exchange at backbone sites that are involved in hydrogen bonds (e.g., in α-helices or β-
sheets) is much slower. HDX at these sites is mediated by structural fluctuations that lead to 
the transient disruption of hydrogen bonds, coupled with backbone N-H exposure to the 
solvent. Ligand binding usually stabilizes the protein, thereby reducing HDX rates. The 
largest changes tend to occur in the vicinity of the binding site, although allosteric effects can 
play a role as well.50-51 It is also possible that some segments exhibit higher HDX rates after 
ligand binding, corresponding to local enhancements in protein dynamics.48,53-55 
In the current work we use HDX/MS for exploring the response of Pin1 to 
[CRYPEVEIC] binding. Especially in cases where X-ray crystallographic data are not 
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available, HDX/MS can provide important insights into the nature of protein-ligand 
interactions.50-51 Also, our aim was to identify highly mobile sequence regions in the Pin1-
[CRYPEVEIC] complex. The presence of such dynamic elements often prevents proteins 
from crystallizing. It is likely that issues of this type were responsible for the lack of success 
in previous crystallization attempts.10 It has been demonstrated for other proteins that 
HDX/MS can guide the design of truncated protein variants with enhanced crystallization 
propensity.56 Our results demonstrate that [CRYPEVEIC] binding causes marked deuteration 
changes in the Pin1 PPIase domain. Many of these alterations reflect the occurrence of 
ligand-induced stabilization, but interestingly there is also a long sequence stretch that 
becomes more dynamic after [CRYPEVEIC] binding. These data yield novel information on 
the nature of Pin1-ligand interactions, and they provide the foundation for future 
crystallization trials on truncated protein constructs. 
 
5.2. Experimental Section 
5.2.1. Materials.  
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was purchased from Sigma 
(St. Louis, MO, USA), and D2O was from Cambridge Isotope Laboratories (Andover, MA). 
All chemicals were used as received. The Arg14Ala variant of human Pin1 was 
overexpressed in E. coli and isolated as described.10,57 [CRYPEVEIC] was purchased from 
EZBiolab (Westfield, IN). The presence of the cyclic form was verified by ESI-MS, which 
resulted in a mass of 1109.5 Da, 2 Da less than expected for the linear amino acid sequence. 
This mass difference corresponds to the loss of two hydrogens as the terminal cysteine 
residues get linked via a -S-S- bond. 
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5.2.2. Backbone Amide Hydrogen/Deuterium Exchange Mass 
Spectrometry.  
The experiments started with 100 µM Pin1 in 10 mM HEPES/100 mM NaCl (pH 7.7). 
[CRYPEVEIC]-bound samples were prepared by adding 2 µL of 25 mM [CRYPEVEIC] in 
water to 13 µL of Pin1 solution, resulting in a five-fold molar excess of ligand. These 
mixtures were pre-equilibrated for 24 h at 4 °C. Deuteration was conducted at room 
temperature. HDX was initiated by addition of 9 volumes of D2O-based labeling buffer 
which had the same salt concentration as the stock solution, for a final measured pH of 7.7 
and a protein concentration of 10 µM. For Kd ≈ 0.5 µM10 the fraction of bound protein under 
HDX conditions was estimated to be 99%. 30 µL aliquots were removed at various time 
points ranging from 1 to 360 min after initiating of labeling. These aliquots were quenched at 
pH 2.4 by addition of HCl on ice, followed by flash freezing in liquid nitrogen and storage at 
-80 °C. For spatially-resolved HDX/MS experiments, the aliquots were rapidly thawed to ~0 
°C and manually injected into a nanoACQUITY UPLC with HDX technology (Waters, 
Milford, MA)58 for desalting and peptide separation within 15 min on an equilibrated 
reversed phase column (BEH C18 1.7 µm, 1 mm × 100 mm) using a water/acetonitrile 
gradient in the presence of 0.1% formic acid at 35 µL min-1 . Online digestion was performed 
on a POROS pepsin column (2.1 mm × 30 mm) from Life Technologies/Applied Biosystems 
(Carlsbad, CA) at room temperature. The temperature for peptide trapping and reversed 
phase separation was set to 1 °C. Blank (water) injections in-between protein injections 
ensured the absence of sample carryover. 
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Mass analysis of peptides was performed on a Waters Synapt HDMS instrument with 
source and desolvation temperatures of 80 and 300 °C, respectively, a cone voltage of 30 V, 
and an electrospray voltage of 2.8 kV. The identity of each peptide was confirmed by tandem 
MS based on the known Pin1 sequence. Zero time point controls (m0) for the correction of in-
exchange were performed by exposing Pin 1 to quenching buffer, followed by D2O exposure, 
resulting in the same final solution composition as for all other samples. Controls for fully 
exchanged Pin1 (m100, for the correction of back exchange) were prepared by incubating 30 
µM Pin 1 in labeling solution at pH 2.0 for 6 days. Biolynx 4.1 (Waters) and HX-Express59 
were employed to analyze the centroid mass of all peptides as a function of labeling time. 
Deuteration levels (%D) were determined as  
 
  %100)(
)(%
0100
0 ×
−
−
=
mm
mmD     (5.1) 
 
Average deuteration differences for Figs. 5.6 were calculated as  
 
∑ −= )%(%1 ][ freeCRYPEVEIC DDNdifferenceaverage   (5.2) 
 
The sum extends over the N = 6 time points that were measured for each peptide. All 
measurements were performed in triplicate. Error bars represent standard deviations. The 
Pin1 sequence numbering used here for reporting our data is consistent with that commonly 
used in the literature9, where the active site cysteine corresponds to position 113. Hence, the 
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N-terminal residue is referred to as Lys6 (instead of Lys1). This implies that after the HDX 
analysis all residue numbers had to be increased by five. 
 
5.3. Results and Discussion 
Peptic digestion of Pin1 under HDX conditions resulted in 28 identifiable peptides, 
corresponding to a sequence coverage of 80 % (Figure 5-2). Even without any data 
processing, it is evident that the presence of [CRYPEVEIC] has noticeable effects on the 
structural dynamics of  
 
Figure 5-2: Sequence and secondary structure elements of Pin1, with the conventionally 
used residue numbering.9 Solid lines represent peptides used for the graphic representation of 
deuteration levels in Figs. 5-5, 5-6. Dashed lines represent redundant peptides.  
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Pin1. The peptide behavior can be categorized into three groups as illustrated in Figure 5-3. 
Some peptides exhibited only very minor differences in their deuteration kinetics upon 
addition of the ligand (e.g., residues 140-160, Figure 5-3A). Others showed significantly 
reduced deuteration in the presence of [CRYPEVEIC], indicating the occurrence of ligand-
induced rigidification (e.g., 139-151, Figure 5-3B). Interestingly, there were also some 
segments where deuteration was enhanced after [CRYPEVEIC] binding, such as 74-86 
(Figure 5-3C).  
A comprehensive overview of the spatially-resolved HDX kinetics is provided in 
Figure 5-4. These data illustrate that the deuteration behavior of the various Pin1 segments is 
highly dependent on the position within the sequence.  
 
 
Figure 5-3: Unprocessed HDX/MS data for three Pin 1 peptic peptides recorded in the 
absence (black solid lines) and in the presence (red dotted lines) of [CRYPEVEIC] for a 
deuteration time of t = 360 min. The sequence range of the three peptides is indicated along 
the top. 
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Peptides towards the N-terminus display very rapid deuterium uptake, indicating that 
the corresponding protein regions are highly dynamic, with backbone N-H groups that are 
either unprotected or engaged in hydrogen bonds that are only marginally stable. In contrast, 
C-terminal segments exhibit a much higher protection against deuteration, reflecting the 
presence of stable secondary structure. 
 To facilitate a discussion of the Pin1 response to ligand binding, HDX data for a 
labeling time of 1 h were mapped to the X-ray structure of the protein (Figure 5-5). The N-
terminal WW domain is displayed in red, signifying its near-complete deuteration both in the 
presence and in the absence of [CRYPEVEIC]. The extremely dynamic nature of this domain 
is somewhat unexpected, considering that isolated Pin1 WW constructs have served as model 
systems in folding experiments where they were treated as independently stable moieties.60  
 
 143 
 
 
Figure 5-4: Normalized deuteration kinetics of Pin1 peptic peptides (%D, determined on the 
basis of eq. 5.1). Each panel shows data recorded in the absence of ligand (open circles) and 
in the presence of [CRYPEVEIC] (filled symbols). Lines are biexponential fits. Error bars 
represent standard deviations of triplicate measurements. 
 
However, crystallization efforts of the isolated WW domain were unsuccessful for many 
years. Only very recently has it been possible to overcome this problem using a racemic 
mixture in the presence of small-molecule additives.61 These crystallization difficulties have 
been attributed to the highly dynamic nature of the Pin1 WW domain.61 Our HDX/MS data 
are in line with these findings, and they furthermore reveal that the WW domain remains 
highly dynamic even in the context of intact Pin1. The conformational flexibility of the WW 
domain is also consistent with the fact that all existing Pin1 X-rays structures have a number 
of unresolved residues in the N-  
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Figure 5-5: Mapping of the HDX data from Figure 5.4 to the crystal structure of Pin1 for a 
deuteration time of t = 60 min in the absence of ligand (A) and in the presence of 
[CRYPEVEIC]. Colors represent deuteration percentages as indicated in the legend. Gray 
color represents regions that were not covered during peptide mapping.  
 
 
Terminal region.9,12,62 In contrast to the WW domain, the PPIase domain of Pin1 showed 
deuteration kinetics that were much more distinct, consistent with the presence of well-
developed secondary structure. Most of the PPIase domain elements displayed HDX levels 
ranging between 40 and 80% after one hour of deuteration (Figure 5-5, yellow and orange). 
The most protected element is β4 which is deeply buried (Figure 5-5, blue). 
Changes in the deuteration pattern of Pin1 after [CRYPEVEIC] binding are displayed 
in Figure 5-6. Regions that underwent significant alterations upon addition of the ligand are 
highlighted in color, whereas all other segments are shown in gray. The color pattern of 
Figure 5-6 again highlights that ligand-induced changes are confined to the PPIase domain, 
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whereas the WW domain does not interact with [CRYPEVEIC]. This finding is consistent 
with recent chemical shift perturbation results.10  
 
Figure 5-6: Deuteration difference map of Pin1 before and after [CRYPEVEIC] binding, 
calculated on the basis of eq. 5.2. Segments with reduced deuteration after ligand binding are 
represented in blue, while those with enhanced deuteration are shown in red, as indicated in 
the color legend. 
 
Pronounced stabilization is seen for β2, α3, and α4 (Fig. 5-6, blue) which are known to be 
involved in substrate binding. β2 and α4 carry the residues that form the hydrophobic Pro 
binding pocket, whereas α3 comprises the active site Cys113 (cf. Figure 5-1A).10,12 
Intriguingly, the sequence stretch covering residues 61 to 86 displayed elevated deuteration 
in the presence of [CRYPEVEIC], implying the occurrence of enhanced conformational 
dynamics after ligand binding (Figure 5-6, red). Most of these residues fold into a double-
looped structure that connects β1 and α1. X-ray data9 show that at least five N-H sites in this 
region form strong backbone hydrogen bonds. The destabilized region identified here 
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comprises the basic residues Lys63, Arg68, and Arg69 which bind the negatively charged 
phosphate of natural pSer-Pro or pThr-Pro substrates.12 NMR shift perturbation data 
suggested that neither Lys63 nor Arg68 interact strongly with [CRYPEVEIC].10 While the 
data of the current work cannot pinpoint individual residues, our HDX/MS results clearly 
demonstrate that residues in the 61-86 range do respond to the presence of the inhibitor. The 
observation of enhanced deuteration strongly suggests that these interactions are unfavorable. 
In other words, [CRYPEVEIC] binding to Pin1 distorts the 61-86 range in a way that 
weakens hydrogen bonding in this segment. Assuming that P4 of [CRYPEVEIC] occupies its 
canonical hydrophobic pocket (Figure 5-1A, blue)12, it seems likely that steric clashes of 
Pin1 with either Y3 or E5 are responsible for destabilizing the 61-86 segment. One 
possibility is that the E5 carboxylate interacts with the positively charged side chains of 
Lys63, Arg68, or Arg69 by acting as a poor phosphate mimic. In any case, the enhanced 
deuterium uptake seen here for the “red” elements of Figure 5-6 originates from a partially 
distorted Pin1 structure that arises as the protein accommodates the inhibitor. The occurrence 
of ligand-induced destabilization in selected protein regions has been reported in a few 
previous studies on other systems.48,53-55 In general, however, this phenomenon is uncommon 
because ligand binding is normally dominated by an overall protein stabilization that 
manifests itself as a reduction in deuteration levels.46-47 Even for the Pin1-[CRYPEVEIC] 
interaction studied here such stabilizing effects are prevalent, seen from the many “blue” 
sequence regions in Figure 5-6. 
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5.4. Conclusions 
The cyclic peptide [CRYPEVEIC] was recently identified as a potent Pin1 inhibitor, 
demonstrating that the presence of a phosphate group is not an absolute prerequisite for Pin1 
binding.10 In other words, the protein will also interact with compounds that do not possess 
the pSer-Pro or pThr-Pro motif found in natural substrates. [CRYPEVEIC] represents a 
promising lead compound for membrane-permeable anticancer agents. Efforts to refine the 
architecture of [CRYPEVEIC]-like compounds would greatly benefit from the availability of 
high resolution X-ray structures that reveal the exact mode of inhibitor binding to Pin1. The 
lack of success in generating suitable crystals of [CRYPEVEIC]-bound Pin1 thus represents 
a major impediment. One approach to deal with this type of problem is the use of “disorder-
depleted” protein constructs that may be more amenable to crystallization. HDX/MS has 
previously been employed for identifying flexible regions that may interfere with crystal 
nucleation and growth.56 The HDX/MS experiments of the current work identify the loop 
region of residues 61-86 as having an elevated degree of disorder after [CRYPEVEIC] 
binding. Protein constructs with truncations in this region may therefore be more amenable to 
the formation of high quality crystals than full-length Pin1. Crystallization trials on such 
constructs are currently underway, and the results of these efforts will be reported elsewhere. 
From a more general perspective, [CRYPEVEIC] binding to Pin1 illustrates that 
ligand interactions can be associated with a complex pattern of stabilizing and destabilizing 
factors. In HDX/MS this leads to scenarios where some regions display lower deuteration 
whereas others are more deuterated in the presence of ligand (blue and red, respectively, in 
Fig. 5-6). There is a small but growing number of protein-ligand systems for which similar 
effects have been reported previously.48,53-55 Recent work has demonstrated that it is even 
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feasible for ligand binding to accelerate HDX kinetics in a global fashion.63 In any case, the 
observation of these and other phenomena illustrates the capability of HDX/MS to probe 
intricate details of biomolecular structure and interactions. 
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Chapter 6. Summary and Future Work 
 
6.1. Summary 
The work described in this thesis showed how both global and local HDX-MS analysis can 
be used for the study of protein structure. Spatially resolved HDX information gives useful 
information about the regions of the protein undergoing conformational changes however, 
global probing is always a useful first experiment. Global probing is usually fast and it cuts 
down on unnecessary experiments. Also, the experimental conditions can be fine-tuned prior 
to enzymatic digests. The ultimate goal in this work was to improve the understanding of 
protein-ligand binding interactions as it pertains to HDX-MS.  
 In Chapter 2, native oxy-Hb and aquomet-Hb were exposed to deuterium. It was 
found that deuteration pattern in these two proteins were quite different with aquomet-Hb 
having a higher deuterium uptake after 6 hours. HDX analysis at the peptide level indicates 
that crystallized Hb does not represent the solution-phase structure adequately. Oxy-Hb also 
showed an increase in the deuterium uptake near the heme binding site. 
 In subsequent studies (Chapter 3), the structural dynamics in hemoglobin and 
myoglobin were studied.  Heme binding to apo-Mb resulted in a decrease in deuterium 
incorporated into the backbone of the protein. This result is in agreement with other HDX 
binding studies. Binding of oxygen to hemoglobin or myoglobin, however, resulted in an 
increase in the uptake of deuterium with hemoglobin exhibiting the larger increase of the two 
proteins. It appears that the increase in measured HDX kinetics was not limited to multimeric 
proteins like hemoglobin.  A thermodynamic model for the different scenarios encountered in 
HDX measurements is thus provided in this chapter. 
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 Having established that protein-ligand interactions can lead to both stabilization or 
destabilization of the protein receptor, Chapter 3 explored the interaction between an 
antibacterial drug target ClpP and ADEP (an antibiotic compound). Binding cause noticeable 
changes at the binding site, but allosteric interactions can be triggered as well. This is 
particularly important for protein-ligand studies that seek to map the binding site of a drug to 
its target. The results also suggest that ligand binding to ClpP induces an opening of the axial 
pore as demonstrated in the increased HDX kinetics in this region. 
Chapter 5 focused on the structural changes in Pin 1 a peptidyl prolyl isomerase. 
CREPEVEIC, a cyclic peptide, is a known inhibitor of Pin 1 however efforts to crystallize 
Pin1-CRYPEVEIC complex have proved unsuccessful. The HDX kinetics of Pin 1 in the 
WW domain remains unchanged in the presence of ligand. The PPIase domain, however, 
shows a dramatic difference before and after ligand binding. Of particular interest is a group 
of residues in the loop region known to interact with the phosphate groups of the ligand. This 
loop became destabilized after ligand binding due to steric effect.  
 
6.2. Future Work 
6.2.1. Application of HDX to Other Proteins 
HDX is a powerful tool for probing the structural dynamics of proteins, but this technique 
works best only for soluble proteins. The size and type of systems that can be studied using 
HDX-MS are endless. The goal is to study larger and more complex systems. The work in 
Chapter 4 looks at ClpP with a small binding partner. It will be interesting to investigate 
ClpP interaction with AAA+ proteins such as ClpX or ClpA. 1-3  Global and peptide analysis 
will help understand how ClpP functions with its natural binding partner. The experiment can 
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also be tuned to look at the structural changes in ClpA (ClpX) as a function of binding to 
ClpP. Another interesting class of protein to study is integral membrane proteins. 
Integral membrane proteins represent a large proportion of the current drug targets which 
indicates their role in cellular processes. Membrane proteins are water insoluble and prone to 
aggregation. They represent the most difficult proteins to study by HDX-MS. Previous MS 
structural studies have utilized detergents as solubilizing agents which allows the acquisition 
of global HDX information. 4-5  It will be interesting to explore the development of improved 
HDX-MS protocols for membrane proteins  
 
6.2.2. Application of HDX to Intrinsically Disordered Proteins (IDPs) 
IDPs represent a special family of proteins lacking a unique tertiary structure at physiological 
pH. IDPs are predicted to perform various function and they have been shown to be 
associated with human diseases like cancer and neurodegenerative diseases.6  HDX is 
routinely used to detect disordered regions in a protein. The ability of HDX to report on the 
structure of the polypeptide chain gives it an advantage over other optical methods that rely 
of select chromophores. HDX has been successfully applied in the study of the interaction 
between ACTR (activator of thyroid and retinoid receptors) and CBP (binding domain of the 
CREB binding protein).7 Extending this technique to other IDPs would be very informative. 
   
 
 
 
 
 
 
 160 
 
6.3. References 
1. Kress, W.; Maglica, Z.; Weber-Ban, E., Clp chaperone-proteases: structure and 
function. Res. Microbiol. 2009, 160 (9), 618-628. 
 
2. Baker, T. A.; Sauer, R. T., ClpXP, an ATP-powered unfolding and protein-
degradation machine. Biochim.  Biophys. Acta 2012, 1823, 15-28. 
 
3. Choi, K.-H.; Licht, S., Control of Peptide Product Sizes by the Energy-Dependent 
Protease ClpAP. Biochem. 2005, 44, 13921-13931. 
 
4. Pan, Y.; Stocks, B. B.; Brown, L.; Konermann, L., Structural Characterization of an 
Integral Membrane Protein in its Natural Lipid Environment by Oxidative Methionine 
Labeling and Mass Spectrometry. Anal. Chem. 2009, 81, 28-35. 
 
5. Pan, Y.; Ruan, X.; Valvano, M. A.; Konermann, L., Validation of Membrane Protein 
Topology Models by Oxidative Labeling and Mass Spectrometry. J. Am. Soc. Mass 
Spectrom. 2012, 23, 889-898. 
 
6. Forman-Kay, J. D.; Mittag, T., From Sequence and Forces to Structure, Function, and 
Evolution of Intrinsically Disordered Proteins. Structure 2013, 21 (9), 1492-1499. 
 
7. Keppel, T. R.; Howard, B. A.; Weis, D. D., Mapping Unstructured Regions and 
Synergistic Folding in Intrinsically Disordered Proteins with Amide H/D Exchange Mass 
Spectrometry. Biochemistry 2011, 50 (40), 8722-8732. 
 
 
 
  
 
161 
 
Appendix I-Permissions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title: Mass Spectrometry Methods for Studying Structure and 
Dynamics of Biological Macromolecules 
  
 
162 
 
Author: Lars Konermann, Siavash Vahidi, Modupeola A. Sowole 
Publication: Analytical Chemistry Publisher:  American 
Chemical Society Date: Jan 1, 2014 
Copyright © 2014, American Chemical Society 
 
 
 
 
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE 
 
This type of permission/license, instead of the standard Terms & Conditions, is sent to you 
because no fee is being charged for your order. Please note the following: 
 
 
Permission is granted for your request in both print and 
electronic formats, and translations. 
If figures and/or tables were requested, they may be adapted or used in part. 
Please print this page for your records and send a copy of it to 
your publisher/graduate school. 
Appropriate credit for the requested material should be given 
as follows: "Reprinted (adapted) with permission from 
(COMPLETE REFERENCE CITATION). Copyright 
(YEAR) American Chemical Society." Insert appropriate 
information in place of the capitalized words. 
One-time permission is granted only for the use specified in 
your request. No additional uses are granted (such as derivative 
works or other editions). For any other uses, please submit a 
new request. 
 
 
 
If credit is given to another source for the material you requested, 
permission must be obtained from that source. 
 
 
 
 
 
 
  
 
163 
 
 
SPRINGER LICENSE 
TERMS AND CONDITIONS 
 
May 27, 2015 
 
 
 
This is a License Agreement between Modupeola A Sowole ("You") and Springer ("Springer") provided 
by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Springer, and the payment terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see information listed at 
the bottom of this form. 
 
License Number 3636001051751 
License date May 25, 2015 
Order Content Publisher Springer 
 
Order Content 
Publication 
Journal of The American Society for Mass Spectrometry 
Order Content Title Comparative Analysis of Oxy-Hemoglobin and Aquomet-Hemoglobin by 
Hydrogen/Deuterium Exchange Mass Spectrometry 
Order Content Author Modupeola A. Sowole 
Order Content Date Jan 1, 2013 
Volume number 24 
Issue number 7 
Type of Use Thesis/Dissertation 
Portion Full text 
Number of copies 10000 
 
Author of this Springer 
article 
Yes and you are a contributor of the new work 
Order reference number None 
 
Title of your thesis / 
dissertation 
 
Expected completion 
date 
Hydrogen Exchange Mass Spectrometry for Studying Protein-Ligand Interactions 
 
 
Aug 2015 
  
 
164 
 
Estimated size(pages) 200 
Total 0.00 USD 
Terms and Conditions 
Introduction 
The publisher for this copyrighted material is Springer Science + Business Media. By clicking "accept" in connection with 
completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the 
Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your 
Rightslink account and that are available at any time at http://myaccount.copyright.com). 
Limited License 
With reference to your request to reprint in your thesis material on which Springer Science and Business Media control the copyright, 
permission is granted, free of charge, for the use indicated in your enquiry. 
Licenses are for one-time use only with a maximum distribution equal to the number that you identified in the licensing process. 
This License includes use in an electronic form, provided its password protected or on the university’s intranet or repository, 
including UMI (according to the definition at the Sherpa website: http://www.sherpa.ac.uk/romeo/). For any other electronic use, 
please contact Springer at (permissions.dordrecht@springer.com or permissions.heidelberg@springer.com). 
 
The material can only be used for the purpose of defending your thesis limited to university-use only. If the thesis is going to be 
published, permission needs to be re-obtained (selecting "book/textbook" as the type of use). 
Although Springer holds copyright to the material and is entitled to negotiate on rights, this license is only valid, subject to a courtesy 
information to the author (address is given with the article/chapter) and provided it concerns original material which does not carry 
references to other sources (if material in question appears with credit to another source, authorization from that source is required as 
well). 
Permission free of charge on this occasion does not prejudice any rights we might have to charge for reproduction of our copyrighted 
material in the future. 
Altering/Modifying Material: Not Permitted 
You may not alter or modify the material in any manner. Abbreviations, additions, deletions and/or any other alterations shall be 
made only with prior written authorization of the author(s) and/or Springer Science + Business Media. (Please contact Springer at 
(permissions.dordrecht@springer.com or permissions.heidelberg@springer.com) 
Reservation of Rights 
Springer Science + Business Media reserves all rights not specifically granted in the combination of (i) the license details provided 
by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
Copyright Notice:Disclaimer 
You must include the following copyright and permission notice in connection with any reproduction of the licensed material: 
"Springer and the original publisher /journal title, volume, year of publication, page, chapter/article title, name(s) of author(s), figure 
number(s), original copyright notice) is given to the publication in which the material was originally published, by adding; with kind 
permission from Springer Science and Business Media" 
Warranties: None 
Example 1: Springer Science + Business Media makes no representations or warranties with respect to the licensed material. 
Example 2: Springer Science + Business Media makes no representations or warranties with respect to the licensed material and 
adopts on its own behalf the limitations and disclaimers established by CCC on its behalf in its Billing and Payment terms and 
conditions for this licensing transaction. 
Indemnity 
You hereby indemnify and agree to hold harmless Springer Science + Business Media and CCC, and their respective officers, 
directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as 
specifically authorized pursuant to this license. 
No Transfer of License 
This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without 
Springer Science + Business Media's written permission. No 
Amendment Except in Writing 
This license may not be amended except in a writing signed by both parties (or, in the case of Springer Science + Business 
Media, by CCC on Springer Science + Business Media's behalf). 
  
 
165 
 
Objection to Contrary Terms 
Springer Science + Business Media hereby objects to any terms contained in any purchase order, acknowledgment, check 
endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and 
Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are 
incorporated herein), comprise the entire agreement between you and Springer Science 
+ Business Media (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established 
by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions 
shall control. 
Jurisdiction 
All disputes that may arise in connection with this present License, or the breach thereof, shall be settled exclusively by arbitration, 
to be held in The Netherlands, in accordance with Dutch law, and to be conducted under the Rules of the 
'Netherlands Arbitrage Instituut' (Netherlands Institute of Arbitration).OR: 
All disputes that may arise in connection with this present License, or the breach thereof, shall be settled exclusively 
by arbitration, to be held in the Federal Republic of Germany, in accordance with German law. Other terms and 
conditions: 
v1.3 
 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No 
 
 
payment is required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 166 
 
 
 
 
 
 
Title: Effects of Protein–Ligand Interactions on 
Hydrogen/Deuterium Exchange Kinetics: Canonical and 
Noncanonical Scenarios 
Author: Modupeola A. Sowole, Lars 
Konermann Publication: Analytical Chemistry 
Publisher: American Chemical Society Date: Jul 1, 2014 
Copyright © 2014, American Chemical Society 
 
 
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE 
 
This type of permission/license, instead of the standard Terms & Conditions, is sent to you 
because no fee is being charged for your order. Please note the following: 
 
 
Permission is granted for your request in both print and 
electronic formats, and translations. 
If figures and/or tables were requested, they may be adapted or used in part. 
Please print this page for your records and send a copy of it to 
your publisher/graduate school. 
Appropriate credit for the requested material should be given 
as follows: "Reprinted (adapted) with permission from 
(COMPLETE REFERENCE CITATION). Copyright 
(YEAR) American Chemical Society." Insert appropriate 
information in place of the capitalized words. 
One-time permission is granted only for the use specified in 
your request. No additional uses are granted (such as derivative 
works or other editions). For any other uses, please submit a 
new request. 
 
 
 
 
 
Copyright © 2015  Copyright Clearance Center, Inc. All Rights Reserved.  Privacy statement.  Terms and 
Conditions. Comments? We would like to hear from you. E-mail us at  customercare@copyright.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 167 
 
 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
 
May 27, 2015 
 
 
 
This is a License Agreement between Modupeola A Sowole ("You") and Elsevier ("Elsevier") provided by Copyright Clearance Center 
("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and the payment terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form. 
 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Modupeola A Sowole 
Customer address Department of Chemistry 
London, ON N6G 5B7 
License number 3636000406054 
License date May 25, 2015 
 
Licensed content 
publisher 
Licensed content 
publication 
Elsevier 
 
 
Journal of Molecular Biology 
Licensed content title Activation of ClpP Protease by ADEP Antibiotics: Insights from Hydrogen Exchange Mass 
Spectrometry 
Licensed content author Modupeola A. Sowole,John A. Alexopoulos,Yi-Qiang Cheng,Joaquin Ortega,Lars 
Konermann 
Licensed content date 15 November 2013 
 
Licensed content volume 
number 
Licensed content issue 
number 
425 
 
 
22 
Number of pages 12 
Start Page 4508 
End Page 4519 
Type of Use reuse in a thesis/dissertation 
Portion full article 
Format both print and electronic 
 
Are you the author of this 
Elsevier article? 
Yes 
Will you be translating? No 
 
Title of your 
thesis/dissertation 
Hydrogen Exchange Mass Spectrometry for Studying Protein-Ligand Interactions 
 
Expected completion 
date 
Aug 2015 
Estimated size (number 200 
 168 
 
 
of pages) 
Elsevier VAT number GB 494 6272 12 
Price 0.00 USD 
VAT/Local Sales Tax 0.00 USD / 0.00 GBP 
Total 0.00 USD 
Terms and Conditions 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing 
transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and 
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are 
available at any time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or 
acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that 
material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote 
or in a reference list at the end of your publication, as follows: 
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), 
with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted 
from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier." 
4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your 
work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of 
Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for 
Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided 
by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end 
of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no 
license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's 
Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted 
shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms 
and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if 
never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an 
unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its 
copyright in the materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, 
employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically 
authorized pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other 
person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of 
publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check 
endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and 
Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are 
incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In 
the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing 
and Payment terms and conditions, 
 169 
 
 
these terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for 
any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided 
by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center 
be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than 
a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only unless your license was granted for 
translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A 
professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article. If 
this license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all languages. 
16. Posting licensed content on any Website: The following terms and conditions apply as follows: Licensing material from an 
Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A 
hyper-text must be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at http://www.elsevier.com; Central 
Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as 
that provided by Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at http://www.elsevier.com . 
All content posted to the web site must maintain the copyright information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be 
password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 
year only. You may obtain a new license for future website posting. 
17. For journal authors: the following clauses are applicable in addition to the above: 
Preprints: 
A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value 
added to it by a publisher (such as formatting, copyright, technical enhancement etc.). 
Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear 
more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their 
Accepted Author Manuscript (see below). 
If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of 
researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best 
available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on 
these policies is available on the journal homepage. 
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication 
and which typically includes author-incorporated changes suggested during submission, peer review and editor-author 
communications. 
Authors can share their accepted author manuscript: 
 
 immediately 
via their non-commercial person homepage or blog 
by updating a preprint in arXiv or RePEc with the accepted manuscript 
via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research 
collaboration work-group 
directly by providing copies to their students or to research collaborators for their personal use 
for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an 
agreement 
 after the embargo period 
via non-commercial hosting platforms such as their institutional repository via 
commercial sites with which Elsevier has an agreement 
 
In all cases accepted manuscripts should: 
 
 link to the formal publication via its DOI 
 170 
 
 
 bear a CC-BY-NC-ND license - this is easy to do 
 if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting 
policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article. 
 
Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears 
or will appear in the journal and embodies all value-adding publishing activities including peer review co- ordination, 
copy-editing, formatting, (if relevant) pagination and online enrichment. 
Policies for sharing publishing journal articles differ for subscription and gold open access articles: 
Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have 
access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available 
version. 
Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding 
institution with DOI links back to the formal publications on ScienceDirect. 
If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research 
accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in 
course packs and courseware programs), and inclusion of the article for grant funding purposes. 
Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a 
CrossMark logo, the end user license, and a DOI link to the formal publication on ScienceDirect. Please 
refer to Elsevier's posting policy for further information. 
18. For book authors the following clauses are applicable in addition to the above:  Authors are permitted to place a brief summary of 
their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan 
the printed edition to create an electronic version. Posting to a repository: Authors are permitted to post a summary of their chapter 
only in their institution's repository. 
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print 
or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission 
for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please 
reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted 
publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect. 
 
Elsevier Open Access Terms and Conditions 
You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals 
that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of 
Creative Commons user license. See our open access license policy for more information. 
Terms & Conditions applicable to all Open Access articles published with Elsevier: 
Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in 
such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated. 
The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication 
on ScienceDirect. 
If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to 
another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the 
rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the 
Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the 
user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates 
if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are 
available at http://creativecommons.org/licenses/by/4.0. 
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter 
and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the 
formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not 
represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full 
details of the license are available at 
 171 
 
 
http://creativecommons.org/licenses/by-nc-sa/4.0. 
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial 
purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives 
appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is 
not represented as endorsing the use made of the work. The full details of the license are available at 
http://creativecommons.org/licenses/by-nc-nd/4.0. Any commercial reuse of Open Access articles published with a CC BY NC SA or 
CC BY NC ND license requires permission from Elsevier and will be subject to a fee. Commercial reuse includes: 
 
 Associating advertising with the full text of the Article 
 Charging fees for document delivery or access 
 Article aggregation 
 Systematic distribution via e-mail lists or share buttons 
 
Posting or linking by commercial companies for use by customers of those companies. 
 
20. Other Conditions: 
 
v1.7 
 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is 
required. 
 
 
 
 
 
 
 
 
 
 
 
 
 172 
 
 
 
 
 
NRC RESEARCH PRESS LICENSE 
TERMS AND CONDITIONS 
 
May 27, 2015 
 
 
 
This is a License Agreement between Modupeola A Sowole ("You") and NRC Research Press ("NRC Research Press") provided by 
Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by NRC 
Research Press, and the payment terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form. 
 
License Number 3636001111552 
License date May 25, 2015 
Order Content Publisher NRC Research Press 
 
Order Content 
Publication 
Canadian Journal of Chemistry 
Order Content Title Noncovalent binding of a cyclic peptide inhibitor to the peptidyl-prolyl isomerase Pin1, 
explored by hydrogen exchange mass spectrometry 
Order Content Author Modupeola A. Sowole, Brendan T. Innes, Mahasilu Amunugama, et al 
Order Content Date Jan 1, 2015 
Volume number 93 
Issue number 1 
Type of Use Thesis/Dissertation 
Requestor type Author (original work) 
Format Print and electronic 
Portion Full article 
Order reference number None 
 
Title of your thesis / 
dissertation 
 
Expected completion 
date 
Hydrogen Exchange Mass Spectrometry for Studying Protein-Ligand Interactions 
 
 
Aug 2015 
Estimated size(pages) 200 
Total 0.00 USD 
Terms and Conditions 
 
 
 
 
 
General Terms & Conditions 
  
Permission is granted upon the requester's compliance with the following terms and conditions: 
 
1. A credit line will be prominently placed in your product(s) and include: for books the author, 
book title, editor, copyright holder, year of publication; for journals the author, title of article, 
title of journal, volume number, issue number, and the inclusive pages. The credit line must 
include the following wording: "© 2008 Canadian Science Publishing or its licensors. 
Reproduced with permission," except when an author of an original article published in 
2009 or later is reproducing his/her own work. 
 
2. The requester warrants that the material shall not be used in any manner that may be 
derogatory to the title, content, or authors of the material or to Canadian Science Publishing, 
including but not limited to an association with conduct that is fraudulent or otherwise 
illegal. 
 
3. Permission is granted for the term (for Books/CDs-Shelf Life; for Internet/Intranet-In perpetuity; 
for all other forms of print-the life of the title) and purpose specified in your request. Once term 
has expired, permission to renew must be made in writing. 
 
4. Permission granted is nonexclusive, and is valid throughout the world in English and the 
languages specified in your original request. A new permission must be requested for 
revisions of the publication under current consideration. 
 
5. Canadian Science Publishing cannot supply the requester with the original artwork or a "clean 
copy." 
 
6. If the Canadian Science Publishing material is to be translated, the following lines must be 
included: The authors, editors, and Canadian Science Publishing are not responsible for errors 
or omissions in translations. 
 
v1.4 
 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for 
your reference. No payment is required. 
 
 
 
 
 
 
 
 
 
 
 
 
174 
 
 
 
 
Appendix II-Curriculum Vitae  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
175 
 
 
 
Name: MODUPEOLA SOWOLE 
 
Education 
 
Ph.D. 2011-2015 The University of Western Ontario, Canada. 
 
M.Sc. 2009-2011 The University of Western Ontario, Canada. 
 
M.Sc. 2005-2006 The University of Lagos, Nigeria. 
 
B.Sc. 1998-2002 The University of Lagos, Nigeria. 
 
Selected Scholarships and Awards 
 
Canadian Society of Mass Spectrometry Travel Award                            2014 
 
Graduate Thesis Research Award                                              2013 
Canadian Society for Chemistry Award                          2013 
Research/Work Experience 
 
Research / Teaching Assistant University of Western Ontario 2009-2015 
 
Graduate Fellow   University of Lagos   2008-2009 
 
Graduate/Teaching Assistant  University of Lagos   2005-2006 
 
 
Publications 
 
1. B. T. Innes, M. A Sowole, L. Gyenis, M. Dubinsky, L. Konermann, D. W. Litchfield, 
C. J. Brandl, and B. H. Shilton (2015) "Peroxide-Mediated Oxidation and Inhibition of 
the Peptidyl-Prolyl Isomerase Pin1" Biochim. Biophys. Acta, 1852, 905-912 
 
2. M. A. Sowole, B. T. Innes, M. Amunugama, D. W. Litchfield, C. J. Brandl, B. H. 
Shilton, and L. Konermann (2015) "Noncovalent Binding of a Cyclic Peptide Inhibitor 
to the Peptidyl-Prolyl Isomerase Pin1 Explored by Hydrogen Exchange Mass 
Spectrometry" Can. J. Chem., 93, 44-50  
 
3.  L. Konermann, A. D. Rodriguez, M. A. Sowole, (2014) "Type 1 and Type 2 Scenarios 
in Hydrogen Exchange Mass Spectrometry Studies on Protein-Ligand 
Complexes" Analyst, 139, 6078-6087 
 
  
176 
 
 
4. M. A. Sowole and L. Konermann, (2014) "Effects of Protein-Ligand Interactions on 
Hydrogen/ Deuterium Exchange Kinetics: Canonical and Non-Canonical Scenarios" 
Anal. Chem., 86, 6715-6722 
 
5. L. Konermann, S. Vahidi , and M. A. Sowole, (2014) "Mass Spectrometry Methods for 
Studying Structure and Dynamics of Biological Macromolecules" Anal. Chem., 86, 
213-232 
 
6. M. A. Sowole, J. A. Alexopoulos, Y.-Q. Cheng, J. Ortega and L. Konermann, (2013) 
"Activation of ClpP Protease by ADEP Antibiotics: Insights from Hydrogen Exchange 
Mass Spectrometry" J. Mol. Biol., 425, 4508–4519 
 
7. M. A. Sowole and L. Konermann, (2013) "Comparative Analysis of Oxy- Hemoglobin 
and Aquomet-Hemoglobin by Hydrogen/Deuterium Exchange Mass Spectrometry" J. 
Am. Soc. Mass Spectrom. 24, 997-1005  
 
8. M. A. Sowole and H.-B. Kraatz, (2012) "Electrochemical detection of hepatitis C viral 
NS3-4A protease." Analyst., 137, 1120-1124 
 
 
 
Selected Poster and Oral presentations 
 
1. 2014: M. A. Sowole; Protein-Ligand Interactions Studied by Hydrogen Exchange Mass 
Spectrometry, 27th annual  Tandem Mass Spectrometry Workshop Dec 3-6, Lake Louise 
Alberta Canada. Oral Presentation  
  
2. 2014: M. A. Sowole and L. Konermann; Does Protein-Ligand Binding Generally Induce 
Reduced Deuteration Rates?  Globin Oxygenation Studies Provide Insights Into HDX 
Fundamentals. 62nd ASMS Conference on Mass Spectrometry and Allied Topics. Jun., 
15-19, Baltimore MD, United States. Poster Presentation 
 
3. 2014: M. A. Sowole and L. Konermann; Thermodynamic Aspects of Protein-Ligand 
Interactions Probed by Hydrogen Exchange Mass Spectrometry. 97th Canadian 
Chemistry Conference and Exhibition. Jun., 1-5, Vancouver, B.C, Canada. Oral 
Presentation 
 
4. 2013: M. A. Sowole and L. Konermann; Effector Binding Causes Major Changes in the 
Structure and Dynamics of the ClpP Protease Complex: A HDX/MS Investigation. 61th 
ASMS Conference on Mass Spectrometry and Allied Topics, June 8-14, Minneapolis, 
United State. Oral Presentation 
 
5. 2012: M. Sowole and L. Konermann; Conformational Dynamics of Hemoglobin in 
Different Ligation states studied by HDX mass spectrometry. 60th ASMS Conference on 
  
177 
 
 
Mass Spectrometry and Allied Topics, May 20-24, Vancouver, Canada. Poster 
Presentation 
 
 
